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Abstract 
The development of disease-modifying drugs and differential diagnostic agents is a current focus 
of research in Parkinson’s disease (PD) and one putative target is alpha-synuclein (AS). Recently, 
we reported that two bifunctional compounds composed of a caffeine scaffold attached to nicotine 
(C8-6-N) and 1-aminoindan (C8-6-I) could prevent AS mediated toxicity in a yeast model of PD. 
Although caffeine linked to caffeine (C8-6-C8) did not show any therapeutic potentials, it 
demonstrated the strongest binding to AS. To better understand the biodistribution of C8-6-I, C8-
6-N, and C8-6-C8 in vivo we are developing methods to label the bifunctional compounds with 
Fluorine-18 (18F) to use in positron emission tomography (PET) imaging studies.  Given the 
therapeutic and diagnostic potentials of these bifunctional compounds, it is necessary to conduct 
further preclinical studies to understand their safety and efficacy. The overall goal of this study is 
to establish the tandem mass spectrometric fingerprints of the target compounds which can help in 
metabolite identification and for the development of qualitative and quantitative methods. Also, 
the metabolic profile for C8-6-I, C8-6-N, and C8-6-C8 in human, mouse, and rat liver microsomes 
(HLM, MLM, and RLM) were evaluated. Tandem mass spectrometric studies were performed 
using hybrid quadrupole-time of flight and triple quadrupole-linear ion trap mass spectrometers. 
Metabolite profiling was accomplished using accurate mass measurement and tandem mass 
spectrometry. A significant observation in the fragmentation of C8-6-C8 suggests that a previously 
reported loss of acetaldehyde during caffeine fragmentation is instead a loss of CO2. While the 
caffeine scaffold in C8-6-N, C8-6-I, and C8-6-C8 was metabolically stable, the nicotine and 1-
aminoindan moieties were either cleaved off (dealkylation) or hydroxylated in HLM, MLM and 
RLM indicating that the caffeine moiety may be the preferable spot for the inclusion of 18F 
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radioisotope in these bifunctional compounds. Given the similarity in the metabolic pathways, 
mouse and rat may be useful surrogates for future animal studies of C8-6-I, C8-6-N, and C8-6-C8.  
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1.0 Chapter One: Introduction 
Parkinson’s disease (PD) is ranked the second most common neurodegenerative disorder 
after Alzheimer’s disease (AD), and more than ten million people worldwide are diagnosed 
with PD (1). The development of disease-modifying treatments and differential diagnostic 
agents are important aspects of research in PD. Alpha-synuclein (AS) has been identified 
as one of the putative biological targets for the development of disease-modifying drugs 
and differential diagnostic agents for PD.  AS is an intrinsically disordered protein that is 
thought to be involved in the mobilization of synaptic vesicles for neurotransmission (2, 
3); however, the misfolding of AS is a critical event in the pathogenesis of PD (3). Our 
laboratory has focused on developing novel compounds that can interact with AS and 
ultimately prevent the pathological pathway that leads to PD.   Recently, we reported that 
two bifunctional compounds composed of a caffeine scaffold attached to nicotine (C8-6-
N), and 1-aminoindan (C8-6-I) (Figure 1.1) were the most promising candidates in 
preventing the pathological pathway that leads to PD (3). Although caffeine linked to 
caffeine (C8-6-C8) (Figure 1.1) did not show any therapeutic potential, it demonstrated the 
strongest binding to AS making it a suitable candidate for the development of imaging 
probes for the diagnosis of PD. In view of this new evidence, new research is proposed to 
develop Fluorine-18 (18F) analogues of C8-6-C8, C8-6-N, and C8-6-I as positron emission 
tomography (PET) imaging probes to assess the biodistribution of the bifunctional 
compounds and for the diagnosis of PD. 
Given the therapeutic and diagnostic potentials of these novel bifunctional compounds, it 
is of great importance to determine their metabolic stability at this early stage of drug 
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discovery and development. The evaluation of the metabolic stability of these novel 
bifunctional compounds can provide useful information about their safety and efficacy 
which will contribute to the improvement of the intellectual property of these new chemical 
entities (NCEs).  
 
Figure 1.1 Structure of C8-6-C8, C8-6-N, and C8-6-I  
The overall goal of my research is to determine the metabolic stability of C8-6-I, C8-6-N, 
and C8-6-C8 in human, mouse, and rat liver microsomes (HLM, MLM, and RLM). The 
outcome will be useful in determining the location of 18F incorporation in the imaging 
probes. These studies will provide a reference for future metabolic studies of the stable 
fluorine-19 (19F) analogues of C8-6-I, C8-6-N, and C8-6-C8. Tested compounds and future 
analogues have the potential to be used as therapeutics or diagnostics for PD and the work 
in this thesis will contribute to the development of predictive structural models to maximize 
biodistribution (high brain penetrance and AS selectivity) and minimize metabolic 
degradation (optimize lifetime). Additionally, comparison of the metabolic profile of RLM 
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and MLM with those of HLM will help to identify the most relevant model for future 
animal studies.  
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2.0 Chapter Two: Literature Review  
2.1 Parkinson’s disease 
PD is a chronic neurodegenerative disorder that is associated with the progressive loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) (1). Approximately 
1% and 4% of the general population over the ages of 60 and 80 years, respectively, are 
diagnosed with PD (2). Parkinsonism or Parkinsonian syndrome is a condition with a 
similar clinical appearance as in PD but different etiology; for instance, some patients have 
parkinsonism secondary to antidopaminergic drugs without the pathology of the SNpc (3). 
PD is the most common form of Parkinsonism and is sometimes called "idiopathic 
Parkinsonism", meaning Parkinsonism with no identifiable cause (4, 5). 
2.2  Etiology of Parkinson’s disease 
Previous studies have identified several predisposing factors associated with PD.  
2.2.1 Genetic factors 
It has been reported that about 15% of patients with PD have a first-degree relative who 
has the disease (4). Research has shown that about 5% of patients diagnosed with PD have 
forms of the disease that occurs as a result of a mutation of one of the several specific genes 
(6) and correlations between the incidence of PD and the mutation of specific genes have 
been identified (3). Mutations in genes that code for AS (SCNA) and leucine rich repeat 
kinase 2 (LRRK2; LRRK2) are implicated in PD (7, 8). Genomic multiplication and point 
mutations of SCNA are associated with familial PD (9-12). Additionally, several in vitro 
studies suggest that authentic phosphorylation of SCNA at serine-129 (13-17) but not 
phosphorylation-mimicking mutations (18, 19) results in an increase in fibril formation. 
This suggests that authentic phosphorylation of SCNA at serine-129 may be associated with 
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the aggregation phenomenon that leads to PD. G2019S is the most common disease 
associated mutation in LRRK2, and it displays higher kinase activity than the wild-type (3), 
suggesting that overactivation of LRRK2 may be associated with the pathogenesis of PD 
(20). Given that AS deposited in Lewy bodies is highly phosphorylated at serine-129, 
LRRK2 and AS may play a synergistic role in the pathogenesis of PD. A simple way to 
explain this is that LRRK2 is the kinase that mediates phosphorylation of AS(7). 
Interestingly, only one study showed that recombinant AS is phosphorylated by cell lysates 
overexpressing LRRK2 from HEK293 cells (21), however, there is no evidence that 
LRRK2 increases phosphorylation of AS in cell or animal systems (7).  
2.2.2 Biochemical factors 
The loss of dopaminergic neurons in the SNpc of the brain is the primary pathological 
feature of PD. Dopaminergic neurons use dopamine as a neurotransmitter. Dopamine is a 
catecholaminergic neurotransmitter responsible for transmitting signals between the SNpc 
and the corpus striatum to produce smooth purposeful movement (22-25). Loss of 
dopaminergic neurons results in abnormal nerve firing patterns within the brain that cause 
impaired movement (22-25). Previous research has shown that patients diagnosed with PD 
have lost about 60 to 80% of dopaminergic neurons in the SNpc prior to the onset of 
symptoms (22-25).  
The biochemical consequence of the progressive loss of dopaminergic neurons in the SNpc 
is the gradual denervation of the striatum, the main target projection for the SNpc neurons 
(24, 25). Other target regions of these neurons include the intralaminar and parafascicular 
nuclei of the thalamus, the globus pallidus, and the subthalamic nucleus (24, 25). Dopamine 
denervation of the putamen, the motor portion of the striatum, leads to many of the motor 
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symptoms of PD and symptoms develop when striatal dopamine depletion reaches 50–70% 
(24, 25).  
2.2.3 Environmental factors 
Previous studies have implicated exposure to certain toxins such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) in the etiology of PD (3). MPTP, a common 
contaminant of the opioid 1-methyl-4-phenyl-propionoxypiperidine (MPPP), is a lipophilic 
drug that crosses the blood-brain barrier (BBB) and is metabolized by monoamine oxidase-
B to the neurotoxic form, 1-methyl-4-phenylpyridinium (MPP+) (26). MPP+ selectively 
destroys dopaminergic neurons in the SNpc. MPP+ is also an uncoupler of the electron 
transport chain coupled oxidative phosphorylation pathway thereby leading to the release 
of free radicals which contribute to cell destruction. The neurotoxic effect of MPP+ is 
mediated through a high-affinity uptake process in the dopaminergic nerve terminal that 
would otherwise mediate the reuptake of excess dopamine in the synaptic cleft (26).  
Furthermore, exposure to compounds such as amphetamine (27, 28) and the insecticide 
paraquat (29-31) has been reported to increase the incidence of the disease. Amphetamine 
and paraquat mediate their neurotoxic effect by binding to AS at the N-terminus and 
causing it to adopt a more compact conformation (32) which is more prone to the 
aggregation phenomenon that leads to PD. 
Given the implication of AS misfolding in the etiology of PD, it is essential to understand 
how the structure of AS affects its function. Such information will be useful in developing 
novel compounds that can maintain the structural integrity of AS, thereby preventing the 
misfolding pathway that leads to PD.  
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2.3 Structure-function relationship of alpha-synuclein 
Synucleins are a group of secondary structural proteins which include alpha-, beta-, and 
gamma-synuclein (33). AS is encoded by the SCNA gene and there are at least four known 
isoforms of AS encoded by the same SCNA gene in humans and produced through 
alternative splicing (51). These variants are characterized by their unique number of amino 
acids and aggregation potentials (51). Furthermore, the high molecular weight isoforms 
(containing about 140 amino acids) retain all the sites responsible for post-translational 
modifications (52) while the low molecular weight isoforms (containing 112,126 or 98 
amino acids) do not retain these sites and may be predisposed to abnormal aggregation (33, 
52). This indicates that post-translational modification may be a predisposing factor to 
amyloidosis. AS is mainly expressed in the brain at the presynaptic terminals where it is 
thought to play a significant role in the mobilization of synaptic vesicles for the exocytotic 
release of neurotransmitters into the synaptic cleft (53, 54).  Furthermore, AS has been 
reported to account for up to 1% of total protein in soluble cytosolic brain fractions. This 
suggests that it may play a significant role in neuronal function (53). Although AS is mostly 
an intracellular protein, it has also been found in extracellular fluids such as cerebrospinal 
fluid (CSF), blood, and plasma (55-59).  
The structure of the major variant (AS-140) can be divided into two functionally distinct 
regions namely, the N and C terminal (33). The N- terminal region ranges from 1 to 103 
amino acid residues and contains amphipathic apolipoprotein binding helical motifs, which 
are responsible for binding lipids such as phospholipids (33, 60). This binding to 
phospholipids induces AS to adopt a helical conformation (60), which is critical for its role 
in neurotransmission (61). The N-terminal also includes a hydrophobic region, the non-
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amyloid-β-component which is responsible for protein-protein interactions (60). This 
protein-protein interaction induces AS to adopt a beta sheet conformation which is a critical 
event in the prion-like aggregation phenomena associated with PD (60, 61). A unique 
feature of this prion-like aggregation phenomena is permissive templating, in which the 
misfolded AS interacts with a normal AS and converts it to an amyloidogenic form (62-
64). The aggregation of the misfolded AS results in the formation of insoluble fibrils and 
their subsequent inclusion in Lewy bodies (61). The C-terminal region has been suggested 
to be involved in mediating interactions of AS with other cytosolic or membrane-bound 
proteins (60, 62). 
2.4 Diagnosis of Parkinson’s disease 
Clinical diagnosis of PD is mostly based on the triad motor symptoms: resting tremors, 
rigidity and bradykinesia, non-motor symptoms such as constipation, anosmia, cognitive 
dysfunction, depression, and dysautonomia (33-36), as well as postmortem pathological 
examination. The clinical diagnosis of PD can be less challenging when obvious signs and 
symptoms are present, as well as good response to levodopa treatment; however, diagnosis 
becomes more challenging at the onset of the disease due to similar signs and symptoms 
associated with PD and other neurodegenerative disorders such as PD with dementia 
(PDD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) (36). This 
implies that the only definitive confirmation of PD remains postmortem pathological 
examination where progressive degeneration of dopaminergic neurons at the SNpc along 
with AS-rich Lewy bodies are observed (35, 37, 38). Consequently, about 15% of patients 
diagnosed with PD do not strictly meet the clinical criteria for the disease (39) and 
postmortem pathological examination of the diseased brain show a different diagnosis in 
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about 35% of PD patients (40-43). The misdiagnosis of PD can be explained by the 
overlapping neuropathological, cognitive and clinical profile of PD with several other 
neurodegenerative disorders (33). For example, depending on the stage of the disease, 
dementia is present in 10% to 80% of PD patients (44, 45) and so the cognitive profile of 
PDD overlaps with DLB and MSA (33). 
Clearly, accurate diagnosis presents a serious problem in PD and recent research has 
focused on developing accurate diagnostic tools that would be useful for early detection, 
as well as tracking of the disease progression. Early detection of the disease will allow 
administration of disease-modifying treatments and most likely circumvent the onset of 
motor symptoms. To develop a putative biomarker, an understanding of the molecular and 
biochemical mechanism of the disease will be an inevitable step. There is also a good 
chance that such a putative biomarker will provide a novel target for drug discovery and 
development in PD.   
Given the implication of AS in the pathophysiology of PD, AS might be a good candidate 
for diagnosis of PD. Furthermore, the fact that the misfolding of AS is a critical event in 
the pathogenesis of PD implies that aberrant AS may be present in the early stages of the 
disease. In addition, a point mutation in the SCNA gene has been implicated in familial PD 
(11, 46). Also, genetic risk factors involving relatively rare duplications or triplications of 
the SCNA gene locus result in elevated AS in both brain and blood (33, 47). Hence, AS in 
plasma, serum or CSF may serve as a useful diagnostic marker for PD (33). Several studies 
have identified pathological AS in CSF, blood, and saliva (48-50).  
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2.5 Assay of alpha-synuclein in peripheral tissues and body fluids 
As previously discussed, the non-motor symptoms of PD are usually present at the onset 
of the disease before the classical clinical symptoms appear (51). Estimation of 
pathological AS in these affected tissues might be useful in early diagnosis of PD. 
Pathological AS in solid tissues, such as within Lewy bodies and Lewy neurites, has been 
visualized in multiple peripheral tissues using immunohistochemistry (33). Furthermore, 
several analytical techniques such as western blot, enzyme-linked immunosorbent assay 
(ELISA), luminex assay and mass spectrometry have been used to assay for total AS, as 
well as oligomeric and phosphorylated AS in body fluids such as CSF, plasma, and serum. 
The variation in the specificity, sensitivity, and precision of these analytical techniques 
account for variations in the assay. However, not one method appears to be entirely better 
than the other as each has its advantages and disadvantages (33).  
2.5.1 Alpha-synuclein in peripheral tissues 
Ante-mortem and post-mortem tissue samples have been studied for the presence of 
pathological AS. These tissues include cardiac plexus (52), sympathetic ganglia (52, 53), 
gastric myenteric plexus (54), colonic tissue (55-59), gastrointestinal tract (GIT) 
(53),cardiac sympathetic nervous system (60), heart (61, 62), salivary gland (63-65), and 
vagus nerve (65, 66). However, the outcome of assays using these tissues is quite variable. 
These variabilities can be caused by different methods of AS analysis, the severity of PD 
between studies, site of biopsy collection, specificity and sensitivity of the applied 
analytical method and cohort size (33, 67). To overcome these challenges associated with 
the measurement of pathological AS in peripheral tissues, standardized protocols for 
sample collection as well as validated analytical techniques are needed (33). 
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2.5.2 Alpha-synuclein in body fluids 
2.5.2.1 Cerebrospinal fluid  
There is evidence indicating that CSF AS may be the most consistent, sensitive, and 
specific marker for the diagnosis of PD (33). Assays of total CSF AS have been reported 
to be 61 to 94% sensitive and 25 to 64% specific for distinguishing PD from controls (67-
71). 
 It has been observed that while monomeric AS is not affected in PD (72, 73), both 
oligomeric (70, 74, 75) and phosphorylated (71, 76) AS increased in PD patients compared 
with the control group. Several studies have shown that CSF AS may be useful in the 
differential diagnosis of PD and several other neurodegenerative disorders (69, 77, 78). 
Although CSF seems to be the best specimen for diagnosis of PD, the relatively invasive 
nature by which it is obtained makes the procedure almost impracticable (67). 
2.5.2.2 Plasma and serum 
Given the less invasive nature by which plasma and serum are collected as well as its 
availability, plasma and serum may be the most appropriate clinical specimen for assay of 
pathological AS (33). Assays of the levels of serum AS showed conflicting results finding 
either that they are unaffected in PD patients (79) or are decreased compared with control 
groups in a larger cohort (80). Similarly, several conflicting results have been reported for 
the measurement of total plasma AS using ELISA (74, 81-83), western blot (84), mass 
spectrometry (82) and luminex assay (67, 85). The reason for the differing results can be 
explained by the variation in the analytical techniques used for the study.  
Furthermore, a recent study has shown that total plasma AS measured with ELISA 
decreased in both familial and sporadic PD patients compared with the control groups (86). 
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The authors suggested that the lack of significance could be attributed to the small cohorts 
in the familial group (86). The conflicting results in studies assessing plasma AS could be 
caused by factors such as hemolysis, contamination of platelets in plasma, inadequate age-
matched controls, and variation in the specificity and sensitivity of the analytical 
techniques used (67).  
A way to overcome some of these confounders may be to assay exosomal AS (33). 
Measurement of exosomal AS has shown diagnostic sensitivity and specificity comparable 
to those determined by CSF AS (87), making it potentially valuable in the diagnosis of PD 
and determination of disease severity (33). Another possible way to minimize the 
confounding factors associated with measurement of plasma AS is to assay for pathological 
variants of AS (33). For example, oligomeric AS has been reported to either increase (81, 
88) or be unaffected (74, 82, 89) in PD patients compared with controls while 
phosphorylated AS is increased in PD patients compared with controls (82). However, the 
interpretation of this report should be handled with caution as the study involved only a 
small cohort. 
2.5.2.3 Blood 
As red blood cells (RBC) are a significant source of AS, accounting for about 99% of its 
blood levels, RBC may serve as a potential specimen for diagnosis of PD (33). Several 
studies involving the assay of total RBC AS have shown controversial results (47, 90). The 
variation could be accounted for by differences in the analytical technique used and cohort 
size. To validate the potential of blood as a specimen for accurate diagnosis of PD, further 
studies should be conducted to determine the effect of PD on blood AS and RBC count 
which could cause alterations in AS levels (33). 
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2.5.2.4 Saliva 
As saliva is a readily available specimen compared to other body fluids already discussed, 
salivary AS may be a good candidate for diagnosis of PD; however, assays of unstimulated 
salivary AS using western blot, luminex or mass spectrometry showed no significant 
difference in either the cellular component, supernatant (91) or cellular pellet lysate (76).  
Previous studies have shown conflicting results of either an increase in salivary AS in PD 
patients compared with the control group (92) or no alterations in salivary AS (76, 91). 
Further studies are required to provide a standardized protocol for the collection of saliva, 
as well as the most appropriate method of analysis (33). 
Given the current challenge in the diagnosis of PD by estimation of pathological AS from 
body fluids or tissues, recent research has focused on developing molecular imaging probes 
for diagnosis of PD. The next section will focus on molecular imaging and the application 
of PET imaging probes in the diagnosis of PD. 
2.6 Molecular imaging probes for diagnosis of Parkinson’s disease 
Molecular imaging is one of the most widely used technologies in clinical and preclinical 
studies that help researchers to understand the pathophysiology, and drug treatment 
monitoring of various diseases including neurodegenerative disorders such as PD, by 
providing a real-time visualization for in vivo characterization and qualification of 
biological processes at the molecular and cellular level (93). Molecular imaging consists 
of the imaging probe and imaging modalities. A molecular imaging probe is an agent used 
to visualize, characterize and quantify biological processes in living systems (94, 95).  
The molecular imaging probe exists in a number of forms such as radiotracers, contrast 
agents or molecular beacons (96). A molecular imaging probe consists of a linker, a signal 
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moiety, and a target moiety.  The signal agent usually produces a signal that can be detected 
in vivo to image different tissues. The type of imaging probe used for a given imaging 
modality can be determined by the physical property of the signal moiety; for example, a 
PET imaging probe requires a positron-emitting radionuclide as the signal agent whereas 
a single photon emission computed tomography (SPECT) imaging probe employs a 
gamma-emitting radionuclide (96).  
The targeting moiety interacts with a biomarker in a specific biological process, and such 
targeting ligands include but are not limited to small molecules, peptides, proteins, 
antibodies and its fragments, and nanoparticles (96). The linker used in a molecular 
imaging probe can couple the targeting moiety with the signal agent, minimize the 
interaction between the targeting moiety and the signal agent and, most importantly, 
modify the pharmacokinetics of the imaging probe (96). It is important to mention that 
because many aspects need to be optimized to obtain the best imaging outcome, in some 
cases not all three components - the signal agent, the linker, and the targeting moiety are 
simultaneously present in a molecular imaging probe (96). 
A molecular imaging probe with clinical translation is expected to have high binding 
affinity to the target, high specificity to target, high sensitivity, high contrast ratio, high in 
vivo stability, low immunogenicity and toxicity (96). Several emerging molecular 
neuroimaging modalities have made it possible to non-invasively identify the fundamental 
biological processes involved in several degenerative disorders (93). These molecular 
imaging modalities include magnetic resonance imaging (MRI), x-ray computed 
tomography (CT), PET and SPECT. 
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The advantages of molecular imaging reside in the real-time elucidation of the complex 
biological and metabolic pathways of various diseases at the molecular and cellular levels 
(95) compared to the quantitative estimation of the biological target which can be 
challenged by both variations in analytical techniques and specimen. Additionally, 
molecular imaging provides useful information that makes it possible to diagnose the 
diseases at an early stage as well as conduct therapeutic trials of various disease conditions 
(97). Of all the molecular imaging modalities, PET and SPECT have been used extensively 
in clinical neuroscience for the diagnosis of neurodegenerative disorders such as PD and 
AD; however, we will focus on the application of PET in the diagnosis of PD. 
2.6.1 PET molecular imaging 
PET is a high-performance molecular imaging technique that has found relevant 
applications in medical sciences due to its excellent sensitivity of 10-11-10-12 mol/L and 
limitless depth of penetration (93). The modus operandi of PET involves recording pairs 
of high-energy γ-rays emitted indirectly from the decay of radioisotopes which are 
introduced into the subject (93). Most commonly used PET radioisotopes include 11C, 13N, 
15O, 18F, 64Cu, 68Ga, 82Rb and 166Ho. The positrons emitted from the radioactive decay of 
these imaging probes travel a few millimeters through the surrounding tissue, then they 
lose their kinetic energy rapidly (93). The positrons move slowly and annihilate with 
electrons to generate two 511 KeV γ-rays, which travel in opposite directions (98). Given 
that these radioisotopes have short half-lives (t1/2) such as 
18F:t1/2=109.8 minutes, 
11C: 
t1/2=20.3 minutes, and 
15O: t1/2=2.04 minutes, they need to be made at the site and 
introduced into the subject quickly (99). Of all the radioisotopes, 11C, 15O, and 18F are the 
most frequently used radioisotopes for brain imaging (93). 
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PET scanning with the metabolic tracer 18F-2-Fluoro-2-deoxy-D-glucose ([18F]FDG) is 
widely used for detecting tumors, staging cancers, and drug treatment monitoring because 
cancer cells are actively metabolizing glucose (93). [18F] FDG is a structural analog of 
glucose and when injected into the subject, it is transported into the cell by glucose 
transporters where it is phosphorylated by hexokinase; however, the phosphorylated [18F] 
FDG does not have a transporter; hence it is trapped in the cell. The idea is that trapping 
the intact radiolabeled imaging probe provides information about the target cell.  
Although PET has played a critical role in clinical research, a recent report has suggested 
that PET can be used in preclinical research involving small animal models; for instance, 
the Rat Conscious Animal PET (RatCAP) is a microPET instrument with a spatial 
resolution of 1-2mm and sensitivity of 10-11-10-12 mol/L that has been constructed to allow 
small animal free of anesthesia to be scanned (93). Despite the benefits associated with 
PET, there are two major limitations of the technique and these are the use of high-cost 
cyclotron (100) for the development of radioisotopes and the short t1/2 of the radioisotopes 
(93).  
Several PET imaging probes have been reported to be used for diagnosing several central 
nervous system (CNS) diseases such as 1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-
naphthyl)ethylidene) malononitrile ([18F]-FDDNP) for AD (101), 18F-
dihydroxyphenylalanine ([18F]-DOPA) for PD (102), N-methyl-[11C]2-(4’-
methylaminophenyl)-6-hydroxybenzothiazole termed Pittsburgh Compound-B (PIB) 
([11C]-PIB) for AD (103, 104), [11C]-raclopride for PD, schizophrenia, and depression 
(105, 106), [11C]-1-(2-chrorophynyl)-N-methylpropyl)-3 isoquinoline carboxamide ([11C]-
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PK11195) for AD, multiple sclerosis, and Huntington’s disease (107, 108), [11C]-
flumazenil for epilepsy(109), and [11C]-nicotine for AD (110) (Figure 2.1). 
 
Figure 2.1 PET imaging probes for CNS diseases. 
2.6.1.1 PET molecular imaging in Parkinson’s disease 
It is important to emphasize that PET imaging probes are chosen based on their ability to 
interact with a given molecular target involved in the etiology of a disease condition. Of 
all molecular agents, small molecules have been the most useful in diagnosing CNS 
disorders because of their ability to cross the BBB and be cleared from the tissue at a very 
fast rate (93). Some of these small molecules have a high affinity for specific transporters, 
ion channels or specific receptors such as peripheral benzodiazepine receptor (PBR) while 
others can reflect the enzymatic or metabolic activity of a given biochemical pathway 
involved in various disease conditions (93) such as the glycolytic pathway. 
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As previously mentioned, PD is characterized by the progressive loss of dopaminergic 
neurons in the SNpc (111, 112). By imaging the dopaminergic system, several functional 
and neurochemical changes can be used for early diagnosis, as well as differential diagnosis 
of PD. 
Previous PET studies with 11C-PK11195 for PBR have been used to understand the 
progression of the neurodegenerative process and disease state in PD patients (93). 
Furthermore, several studies suggest that there may be a correlation between the activation 
of the microglia and the loss of dopaminergic neurons in the SNpc (113-117). Microglia 
are known to be involved in the modulation of immune responses in the intact brain and 
become activated in response to inflammation, trauma, ischemia, tumor, and 
neurodegeneration (118, 119). Two PET studies have measured microglial activation using 
11C-PK11195, as well as the availability of the presynaptic dopamine active transporter 
(DAT) using11C-2β-carbomethoxy-3β-(4-fluorophenyl)tropane ( [11C]-CFT) (119) and 
[18F]-DOPA (120). DAT is a membrane-bound protein that is responsible for the high-
affinity uptake of dopamine from the synaptic cleft back into the presynaptic neuron. The 
decrease in DAT may be indicative of loss of dopaminergic nerve terminals (119). Ouchi 
et al., (119) suggested that these in vivo imaging methods play dual roles in monitoring the 
progressive degeneration of dopaminergic neurons and these roles are: alterations in 
neuroinflammatory reactions on the cell-body side and the resulting deletion of nerve 
terminals in the striatum.  
Ouchi et al., (119) studied the binding potential (BP) of [11C]-PK11195 and [11C]-CFT in 
ten early-stage drug-naïve PD patients and ten age-matched healthy subjects and showed 
that [11C]-PK11195 BP in the midbrain is inversely related with [11C]-CFT BP in the 
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putamen, which regulates movement, and directly related to motor severity. This inverse 
relationship was also reported to be positively correlated with the severity of motor 
symptoms (119). This study suggests that the oxidative stress triggered by microglia-
mediated immune response contributes to the loss of dopaminergic nerve terminals 
indicating the importance of early therapeutic intervention with neuroprotective drugs 
(119). 
Another study examined [11C](R)-PK11195 BP and [18F]-DOPA BP using 18 PD patients 
and 11 healthy subjects(120). Their study showed a significant increase in mean levels of 
[11C](R)-PK11195 binding in the pons, basal ganglia, as well as frontal and temporal 
cortical regions compared to the healthy subjects (120). Furthermore, the longitudinal study 
conducted on 8 PD patients showed that their [11C](R)-PK11195 signal remained stable for 
two years (120). The authors suggested that the absence of changes during the longitudinal 
study indicates that microglia are activated early in the disease and their levels remain 
relatively static, possibly driving the disease through cytokine release (120). The 
conclusion of their study agrees with that of Ouchi et al., that the activation of microglia is 
associated with the pathogenesis of PD (119, 120). However, Gerhard et al., reported that 
there is no positive correlation between the levels of microglia activation and the clinical 
severity of PD or putamen [18F]-DOPA uptake (120). [18F]-DOPA PET was the first 
neuroimaging technique suited for measuring the integrity of dopaminergic nerve terminals 
(111, 121). 
These previous studies indicate that PET imaging provides useful information about the 
biochemical and neurological changes associated with PD. Not only can this information 
be used for diagnosis, but also for the discovery of neurotherapeutic agents for PD. Given 
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the benefits associated with PET, further studies are underway to identify imaging probes 
for differential diagnosis, early diagnosis, and drug treatment monitoring of PD. 
2.7 Management of Parkinson’s disease 
Although several drugs can help provide relief from the symptoms of PD, there is currently 
no cure for PD (3). Furthermore, the gold-standard treatment depends on the phase of the 
disease therefore, PD patients are usually on several treatment regimens. These treatment 
regimens can be grouped into pharmacological and non-pharmacological therapies.  
Non-pharmacological therapies include psychosocial intervention methods that can 
augment clinical improvement in PD patients (3). These methods include multiple forms 
of physical exercise such as tai chi or Lee Silverman Voice Treatment (LSVT Global, Inc, 
Tucson, AZ, USA) and speech therapy with the LSVT (122). Furthermore, exercise, 
physical therapy, speech and/or occupational therapy have been reported to have a 
sustainable effect for PD patients by improving their quality of life (122). Despite the 
importance of these non-pharmacological therapies, its relevance becomes useless without 
an augmentation of medical treatments. 
Pharmacological therapies include drugs that provide symptomatic relief of the motor and 
non-motor deficits in PD patients (3). Ayano has previously reported the three different 
categories of medications for PD (3). The first category includes drugs that increase the 
level of dopamine in the brain such as levodopa. The second category involves drugs that 
affect other neurotransmitters in the body with the overall aim of easing the symptoms of 
the disease; for example, anticholinergic drugs interfere with the production or uptake of 
acetylcholine and are effective in reducing tremors. The third category includes drugs that 
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help control the non-motor symptoms of PD; for example, PD patients with depression 
may be prescribed antidepressants. 
Additionally, there are several emerging new therapeutic options such as continuous pump 
therapies; for example, with apomorphine or parenteral levodopa, or the implantation of 
electrodes for deep brain stimulation (122). Furthermore, recent research has revealed that 
novel bifunctional compounds can rescue dopaminergic cell death in a yeast model of PD 
and this will be discussed further in the next section. 
2.8  Novel bifunctional compounds as therapeutic agents for Parkinson’s disease 
Although the misfolding of AS is a critical event in the pathogenesis of PD, the exact cause 
of dopaminergic cell death is not well understood (123). However, it has been suggested 
that increasing the activity of the clearance pathways for the misfolded protein might 
provide improved therapies (124-126). Additionally, since the misfolding and prion-like 
aggregation of AS is a crucial event in the pathophysiology of PD, an emerging therapeutic 
target might be the prevention of the misfolding pathway (32).    
Previous studies suggest that caffeine, nicotine, 1-aminoindan, and metformin might be 
neuroprotective (127-137); however, it is not exactly clear how these compounds exert 
their neuroprotective effects. It was previously hypothesized that compounds which bind 
to AS at the N and C terminals and induce it to adopt a loop conformation could be 
neuroprotective whereas compounds which cause more compact structure could be 
neurotoxic (123). In view of this hypothesis, Kakish et al., used nanopore analysis and 
isothermal calorimetry (ITC) to show that nicotine, caffeine, and 1-aminoindan all bind to 
AS at the N-and C-terminal (32). Their research suggests that caffeine, nicotine, and 1-
aminoindan induce AS to adopt a loop conformation and that the stoichiometry of drug to 
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AS in the complex is 1:1 (32). They also reported that since metformin does not interact 
with the N-terminus, it may exert its neuroprotective effect by inhibiting C-terminal 
cleavage of AS (123). It was previously reported that C-terminal cleavage of AS increases 
the rate of aggregation and aggravates the neurodegeneration and propagation of PD in 
mouse models (138, 139).  
In light of this new evidence, Kakish et al., reasoned that modifications to these 
neuroprotective compounds might increase their efficacy without necessarily increasing 
their toxicity (123). To do this, they prepared bifunctional compounds which are a linked 
combination of any two neuroprotective compounds such as caffeine-nicotine (C8-6-N), 
caffeine-caffeine (C8-6-C8), and caffeine-1-aminoindan (C8-6-I) (123) (with structures 
shown in Figure 1.1). These neuroprotective dimers all had a caffeine scaffold and were 
linked through a six carbon alkyl chain to minimize solubility problems and yet retain 
enough flexibility to allow both moieties to bind simultaneously (123). The dimers were 
screened by nanopore analysis and ITC. Finally, a yeast model of PD which expresses an 
alpha-synuclein-green fluorescent protein (AS-GFP) construct under the control of a 
galactose promoter was used to test the ability of these dimers to interact with AS in a cell 
system (123). Fluorescent microscopy revealed that in 5mM galactose the yeast strain 
would not grow and large cytoplasmic foci were observed (123). This implies that aberrant 
AS might have prevented the growth of the yeast strain. All the dimers and monomers were 
tested however, it was observed that two of the dimers, C8-6-I and C8-6-N at a 
concentration of 0.1μM were the most effective at rescuing yeast from AS-mediated cell 
death (123). This shows that some of the dimers are more effective at rescuing yeast growth 
compared to the monomers, either alone or in combination (123). The study concluded that 
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C8-6-I and C8-6-N are the only dimers that did not cause AS to adopt a more compact 
structure at high concentrations making these dimers the most promising candidates for 
preventing the progression of PD by prion-like aggregation (123). Given that the binding 
constants were in the order of 105M-1, the authors suggested that other factors might be 
responsible for the protective effects of these dimers and these factors include: increased 
clearance of the dimer/AS complexes, inhibition of vesicle clustering, decreased 
expression of AS and inhibition of multimer formation by binding to key intermediates 
(123). 
Since these novel dimers can bind AS, they can be developed as PET imaging probes for 
the diagnosis of PD. To achieve this goal, preclinical studies such as metabolism should be 
conducted. Metabolic studies of these compounds will provide useful information about 
their in vitro lifetime as well as the most appropriate position to include a signal moiety on 
the bifunctional compounds. To conduct the metabolic studies of these novel bifunctional 
compounds, an understanding of the concept of xenobiotic metabolism is essential. 
2.9 Metabolism of xenobiotics 
Xenobiotics are compounds that are foreign to an organism’s normal biochemistry, such 
as drugs and poisons (140). Xenobiotic metabolism is the biotransformation of xenobiotics 
by specific enzyme-mediated pathways. The overall goal of xenobiotic metabolism is to 
facilitate the elimination of toxic compounds that would otherwise accumulate in the body 
at toxic concentrations. This is achieved by a series of enzyme-catalyzed reactions which 
modify the physicochemical properties of the xenobiotic thereby promoting their 
elimination from the body. 
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The liver is the major organ that is responsible for the metabolism of both endogenous and 
exogenous compounds. The liver contains the cofactors and enzymes required for 
xenobiotic metabolism. Xenobiotic metabolism can be divided into phase I, phase II, and 
membrane transporter-mediated processes (141). Lipophilic xenobiotics are often first 
metabolized by phase I enzymes, which function to make xenobiotics more polar and 
provide sites for conjugation reactions while phase II enzymes catalyze conjugation 
reactions and can also directly interact with xenobiotics but more commonly interact with 
metabolites produced by phase I enzymes (141). Furthermore, membrane transporters 
mediate the entry (uptake) and exit (efflux) of xenobiotics across the biological membrane 
(141).  
Phase I reaction can occur by oxidation, reduction, and hydrolysis, (140). Phase I reaction 
is primarily mediated by the cytochrome P450-dependent mixed-function oxidase system 
(P450) and requires reduced nicotinamide adenine dinucleotide (NADPH) as a cofactor. 
Some common enzymes involved in phase 1 metabolism include cytochrome P450 
monooxygenase, flavin-containing monooxygenase, and epoxide hydrolase (141). Phase II 
reactions may occur by methylation, sulfonation, acetylation, glucuronidation, and 
glutathione conjugation. The associated enzymes include methyltransferases, 
sulfotransferases, N-acetyltransferases, uridine diphosphate-glucuronosyltransferase 
(UGT), and glutathione-S-transferase. Uptake transporters such as multispecific solute 
carrier, and efflux transporters such as multidrug-resistance protein mediate the entry and 
exit of xenobiotics respectively across the biological membrane.  
In general, NCEs are one of the most studied xenobiotics because of their tendency to cause 
toxicity to humans and animals. Given that these novel bifunctional compounds that bind 
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AS are NCEs, it is important to determine their metabolic stability at this early stage of 
drug discovery and development.  
Since previous studies have elucidated the metabolic pathway of the monomeric units 
(caffeine, nicotine, and 1-aminoindan) of these novel bifunctional compounds, a review of 
their metabolic pathways will be an excellent guide to understanding the metabolic fate of 
the novel bifunctional compounds. 
2.10 Metabolic pathway of caffeine 
Caffeine is also known as 1,3,7-trimethylxanthine, and it is almost completely metabolized 
with about 3% being excreted unchanged in urine (142). The major reaction involved in 
caffeine metabolism is demethylation. The metabolic pathway of caffeine is shown in 
Figure 2.2 (142, 143). The primary route of caffeine metabolism in humans is the CYP1A2 
mediated N-3-demethylation to form paraxanthine which accounts for about 70-80% of 
metabolite formation (142). Previous in vitro metabolism studies using HLM suggest that 
N-1-demethylation to theobromine accounts for about 7-8% of caffeine metabolism and N-
7- demethylation to form theophylline also accounts for about 7-8% of caffeine metabolism 
(142). The remaining 15% is contributed by the xanthine oxidase-mediated C8-
hydroxylation to form the 1,3,7-trimethyluric acid (142). 
CYP1A2 has been reported to be responsible for about 95% of caffeine metabolism, and 
therefore caffeine is used as a probe drug for monitoring CYP1A2 activity with the relative 
ratios of urinary metabolites used as an indicator of the flux through the metabolic pathway 
(142). It has been suggested that knowledge of the activity of such isozymes is of 
toxicological importance since it has been implicated in the biotransformation of certain 
chemicals to the reactive carcinogenic intermediates (143).  
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Figure 2.2 Primary metabolic pathway of caffeine. 
Previous research reported that the major metabolites of caffeine in urine are paraxanthine, 
1-methylxanthine, 1-methyluric acid, 5-acetylamino-6-formylamino-3-methyluracil, and 
1,7-dimethyluric acid (144). These metabolites are formed by secondary metabolism of 
paraxanthine and are largely mediated by CYP1A2, CYP2A6, N-acetyl transferase 2, and 
xanthine oxidase (144). Previous in vitro studies have implicated CYP2E1 in the formation 
of theobromine and theophylline, whereas studies of recombinant proteins in microsomes 
do not support this but instead suggest that it contributes to the formation of 1,3,7-
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trimethyluric acid (145, 146). Several microsomal metabolism studies have shown that 
CYP2C8, CYP2C9, and CYP3A4 are also involved in the primary metabolism of caffeine 
(145-147). Caffeine has a t1/2 of 4 to 5 hours, and the t1/2 may be prolonged by factors such 
as hepatic disease, age, and pregnancy (144). 
2.11 Metabolic pathway of nicotine 
Six primary metabolites of nicotine have been identified, and in most mammalian species,  
the most important metabolite of nicotine is the lactam derivative, cotinine (148). The 
metabolic pathway of nicotine is shown in Figure 2.3 (148, 149). In humans, about 70– 
80% of nicotine is converted to cotinine, and this biotransformation involves two steps. 
The first step involves the CYP2A6 mediated oxidation to produce nicotine-Δ 1′ (5′) -
iminium ion, which is in equilibrium with 5′-hydroxynicotine, while the second step 
involves a cytoplasmic aldehyde oxidase-mediated oxidation to form cotinine (148). It has 
been suggested that nicotine iminium ion could play a role in the pharmacology of nicotine 
since it is an alkylating agent (150). Nicotine N′-oxide is another primary metabolite of 
nicotine, accounting for about 4–7% of nicotine absorbed by smokers (151). The 
biotransformation of nicotine to nicotine N′-oxide involves a flavin-containing 
monooxygenase 3 (FMO3), which results in the formation of both possible diastereomers, 
the 1′-(R)-2′-(S)-cis and 1′-(S)-2′-(S)-trans-isomers in animals (149, 152). In humans, this 
pathway has been reported to be highly selective for the trans-isomer (149). Previous 
research has shown that only the trans-isomer of nicotine N′-oxide was detected in urine 
after administration of nicotine by intravenous infusion, transdermal patch or smoking 
(152). Nicotine-N-oxide does not appear to be further metabolized to any significant extent, 
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except by reduction back to nicotine in the intestines and this may lead to recycling nicotine 
in the body (151). 
Oxidative N-demethylation of nicotine to nornicotine has been reported (148). A report 
from a study of the differences in nornicotine excretion in smokers during smoking and 
transdermal nicotine treatment shows that although nornicotine is a constituent of tobacco 
leaves, most urine nornicotine is derived from the metabolism of nicotine with less than 
40% coming directly from tobacco (151). For most species, the N-demethylation pathway 
is a minor pathway in the metabolism of nicotine (148). 
Additionally, 3′-hydroxycotinine has been reported to be the main nicotine metabolite 
detected in smokers’ urine (148) which is also excreted as a glucuronide conjugate (151). 
3′-hydroxycotinine and its glucuronide conjugate account for 40–60% of the nicotine dose 
in urine (151, 153). Previous studies have shown that the conversion of cotinine to 3′-
hydroxycotinine in humans is highly stereoselective for the trans-isomer, as less than 5% 
is detected as cis-3′-hydroxycotinine in urine (154, 155). The only 3′-hydroxycotinine 
conjugate detected in urine is the O-glucuronide (153). 
Hecht et al., reported a new pathway for the metabolism of nicotine (156). This pathway 
involves the cytochrome P450 mediated 2’-hydroxylation of nicotine to produce 4-
(methylamino)-1-(3-pyridyl)-1-butanone with 2’-hydroxynicotine as an intermediate. 4-
(methylamino)-1-(3-pyridyl)-1-butanone is also known as nicotine-derived nitrosamine 
ketone (NNK). 2′-hydroxynicotine is reduced to nicotine-Δ 1′ (2′) -iminium ion. 4-
(methylamino)-1-(3-pyridyl)-1-butanone is further oxidized to 4-oxo-4-(3-pyridyl) 
butanoic acid and 4- hydroxy-4-(3-pyridyl) butanoic acid. 
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Figure 2.3 Primary metabolic pathway of nicotine. 
This new pathway has been reported to be potentially significant since 4- (methylamino)-
1-(3-pyridyl)-1-butanone can be converted to carcinogenic NNK(148). However, 
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endogenous production of NNK from nicotine has not been detected in humans or rats 
(157). 
Additionally, nicotine also undergoes phase 2 metabolism, and these conjugation reactions 
are methylation and glucuronidation. The methylation of the pyridine nitrogen leads to the 
formation of nicotine isomethonium ion (also called N -methylnicotinium ion). About 3-
5% of nicotine metabolism is accounted for by the glucuronidation pathway, and this 
reaction is mediated by UGT producing (S)-nicotine-N-β-glucuronide (148). 
2.12 Metabolic pathway of 1-aminoindan 
1-aminoindan has been identified as a metabolite of rasagiline (158). Rasagiline (N-
propargyl-1(R)-aminoindan) is an irreversible inhibitor of monoamine oxidase-B which is 
usually used as a monotherapy in early PD and as a supplement in advanced PD to decrease 
off-time and improve the symptoms of PD in levodopa-treated patients with motor 
fluctuation (159, 160). The metabolism of rasagiline involves two main pathways which 
include N-dealkylation to yield 1-aminoindan and hydroxylation to yield 3-hydroxy-N-
propargyl-1-aminoindan and 3-hydroxy-1-aminoindan (3-OH-AI) (161-163). The 
metabolic pathway of rasagiline is shown in figure 2.4 (164). CYP1A2 has been implicated 
as the major enzyme involved in the metabolism of rasagiline (161-163). Rasagiline also 
undergoes oxidative deamination to form indanone (164). Previous studies suggest that 1-
aminoindan may contribute to the overall neuroprotective and antiapoptotic effects of 
rasagiline (128, 165-167). Furthermore, the hydroxylated metabolites of rasagiline may 
also have potential neuroprotective effects (168).  
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Figure 2.4 Metabolic pathway of rasagiline. 
 No information exists describing the metabolism of the three bifunctional compounds 
identified in previous studies for their ability to bind to AS or protect yeast cells from AS-
induced toxicity. To establish the potential for using these compounds as therapeutic or 
diagnostic probes for PD, we are interested in determining their in vitro hepatic 
metabolism. An understanding of their metabolic profiles will guide us in the design of 18F 
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labeled PET imaging probes and optimization of metabolic stability for treatment 
modalities. 
2.13 Hypotheses 
2.13.1 Hypothesis 1 
Caffeine dissociation is the driving force in the tandem mass spectrometric 
fragmentation of C8-6-C8, C8-6-N, and C8-6-I. 
2.13.1.1 Objective 1 
1. To determine the tandem mass spectrometric fragmentation pathway of C8-6-C8, 
C8-6-N, and C8-6-I. 
2.13.2 Hypothesis 2 
 C8-6-C8, C8-6-N, and C8-6-I undergo in vitro metabolism in HLM, MLM, and 
RLM. 
2.13.2.1 Objective 2 
To determine the metabolic profile of C8-6-C8, C8-6-N, and C8-6-I in HLM, MLM, 
and RLM. 
 
            
 
 
 
 
33 
 
3.0 Chapter Three: Tandem Mass Spectrometric Analysis of Novel 
Bifunctional Compounds for Parkinson’s Disease 
Chukwunonso K. Nwabufo, Anas El-Aneed, Ed S. Krol* 
1. Drug Discovery and Development Research Group, College of Pharmacy and 
Nutrition, University of Saskatchewan, Saskatoon, SK 
 
*Author to whom correspondence should be addressed 
Dr. Ed S. Krol 
Drug Discovery and Development Research Group 
College of Pharmacy and Nutrition 
University of Saskatchewan 
Saskatoon, SK 
Ph: 306-966-2011 
ed.krol@usask.ca 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Graphical Abstract 
 
 
 
 
 
 
 
 
 
 
 
m/z
Signal
m/z
Signal
m/z
Signal
Detector
400.5 320.5
200.5 400.5
400.5400.5
Mass Spectrometric 
Fingerprint
Targeted identification and 
LC-MS/MS method 
development
Single Stage MS MS/MS MS3
Ion 
Source
Quadrupole
Collision cell
Linear ion trap
35 
 
3.1 Abstract 
Rationale 
C8-6-N, C8-6-I, and C8-6-C8 are novel bifunctional compounds that are currently being 
investigated as therapeutics or diagnostics for Parkinson’s disease (PD). In order to probe 
their biological activity, an appropriate analytical method is required. The goal of this study 
is to establish a tandem mass spectrometric (MS/MS) fingerprint for these bifunctional 
compounds.  
Methods 
Accurate mass measurement was performed using a hybrid quadrupole orthogonal time-
of-flight mass spectrometer while multi-stage MS/MS and MS3 analysis were conducted 
using a triple quadrupole-linear ion trap mass spectrometer. Both instruments are equipped 
with an electrospray ionization (ESI) source and were operated in the positive ion mode. 
The source and compound parameters were optimized for all tested bifunctional 
compounds. 
Results 
The MS/MS analysis indicates that the fragmentation of C8-6-N and C8-6-I is not driven 
by caffeine dissociation. A significant observation in our fragmentation of C8-6-C8 
suggests that a previously reported loss of acetaldehyde during caffeine dissociation is 
instead a loss of CO2.  
 
 
36 
 
Conclusion 
The MS/MS analysis of these novel bifunctional compounds revealed diagnostic product 
ions and neutral losses (NLs) for all tested bifunctional compounds. The diagnostic product 
ions can be applied to the future development of liquid chromatography-multiple reaction 
monitoring (LC-MRM) methods for quantitative analysis while the diagnostic NLs can be 
used for targeted identification of these bifunctional compounds in biological matrices. 
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3.2 Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease (2, 169-172). PD is associated with the progressive demise of 
dopamine-producing neurons in the substantia nigra (1, 173). Currently, there is no cure 
for PD, and accurate diagnosis can only be accomplished through post-mortem analysis; 
thus clinical misdiagnosis of PD is not uncommon (39, 174). Given these factors, the 
development of disease-modifying treatments, as well as early stage and differential 
diagnostic agents are important aspects of current PD research. One target under 
investigation for treatment and diagnosis of PD is alpha-synuclein (AS), a 140 amino acid 
intrinsically disordered protein that is known to aggregate and forms oligomeric species 
that are found in Lewy bodies of PD patients, suggesting they play a role in the 
pathophysiology of PD (32, 33). Our laboratory has focused on developing novel 
compounds that can interact with AS and ultimately prevent the pathological pathway that 
leads to PD. Recently, we reported that two bifunctional compounds composed of a 
caffeine scaffold attached to nicotine (C8-6-N), and 1-aminoindan (C8-6-I) (Figure 3.1) 
were the most promising candidates in preventing the pathological pathway that leads to 
PD (123). Although caffeine linked to caffeine (C8-6-C8) (Figure 3.1) did not show any 
therapeutic potential, it demonstrated the strongest binding to AS making it a suitable 
candidate for the development of imaging probes for PD diagnosis.  
Given the therapeutic and diagnostic potentials of these novel bifunctional compounds, it 
is of great importance to conduct further preclinical studies at this early stage of drug 
discovery and development. The preclinical evaluation of the metabolic stability and 
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pharmacokinetics of these novel bifunctional compounds will provide useful information 
about their safety and efficacy.  
Therefore, it is important to establish appropriate analytical methods for the qualitative and 
quantitative analysis of C8-6-N, C8-6-I, and C8-6-C8. Liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS) has become an indispensable analytical tool for 
the identification, structural characterization, and quantitative analysis of pharmaceuticals 
(175-180). The characterization of new chemical entities (NCEs) using MS can be achieved 
through accurate mass measurement and collision-induced dissociation tandem mass 
spectrometric (CID-MS/MS) analysis.   
The elucidation of CID-MS/MS fragmentation pathways for NCEs allows for the 
unambiguous confirmation of their structure, as well as identification of diagnostic product 
ions and neutral losses (NLs), which can subsequently be used for quantitative and 
qualitative analysis, respectively. NL can also be used in the identification of known and 
unknown metabolites in biological and non-biological matrices. For example, Bourcier et 
al., used diagnostic NLs identified from the fragmentation of 28 neurotransmitters and 
related compounds (181-185) to identify expected and unexpected metabolites in 
biological fluids (181). Additionally, Bourcier et al., used diagnostic NLs for the 
unambiguous differentiation of isomers, as well as the identification and localization of 
functional groups (186). In addition, CID-MS/MS analysis allows for the selection of 
diagnostic quantifier and qualifier ions for the development of multiple reaction monitoring 
(MRM) quantitative methods. For instance, a generalized MS/MS fingerprint was 
developed for a series of structurally similar novel drug delivery agents, namely gemini 
surfactants (187-189). Subsequently, the established CID-MS/MS fingerprint was used to 
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develop a targeted MS method for the quantification of these compounds within a cellular 
lysate (190-192). 
In this present study, we evaluated the CID-MS/MS fragmentation behaviour of three novel 
bifunctional compounds, specifically designed for PD. Each bifunctional compound 
consists of a caffeine scaffold attached to nicotine (C8-6-N), 1-aminoindan (C8-6-I) or 
caffeine (C8-6-C8) through a six-carbon alkyl chain (Figure 3.1).  
 
Figure 3.1 Structure of novel bifunctional compounds. 
3.3 Material and Methods 
3.3.1 Materials 
C8-6-I, C8-6-N, and C8-6-C8 were synthesized according to a previously established 
protocol in our laboratory (123). Acetonitrile (HPLC grade purity), methanol (HPLC grade 
purity), chloroform, and formic acid (LC-MS grade purity) were purchased from Fisher 
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Scientific (Fairlawn, NJ) while water was filtered using a Millipore, MilliQ system with a 
Quantum EX cartridge (Mississauga, ON). 
3.3.2 Sample preparation 
Stock solutions of 0.1 mg/mL C8-6-I and C8-6-N were prepared in 100% methanol while 
0.1 mg/mL C8-6-C8 was prepared in 100% chloroform and stored at -80
oC. Subsequently, 
stock solutions of C8-6-I and C8-6-N were diluted 1000x and 10x respectively in 50:50 
acetonitrile/water containing 0.1% LC-MS formic acid while stock solutions of C8-6-C8 
were diluted 5x in acetonitrile containing 0.1% LC-MS formic acid. 
3.3.3 Mass spectrometric analysis 
3.3.3.1 Single-stage MS analysis 
Bifunctional compounds were analyzed using an AB SCIEX QSTAR XL quadrupole 
orthogonal time-of-flight hybrid mass spectrometer (QqToF-MS) equipped with 
electrospray ionization (ESI) source (AB SCIEX, Redwood City, CA, USA). Nitrogen was 
used as the ESI nebulizing and drying gas. The instrument was calibrated with a two-point 
external calibration using cesium iodide (CsI, m/z 132.9049, Sigma-Aldrich, Oakville, ON, 
Canada) and sex pheromone inhibitor iPD1 (m/z 829.5393, Bachem Bioscience Inc., PA, 
USA). Samples were directly infused into the mass spectrometer at a flow rate of 10 
µL/min using an integrated Harvard syringe pump through a Turbo ionspray source with a 
needle voltage of 5500 V. The mass spectrometer was operated in the positive ion mode 
with declustering potential of 40 V and focusing potential of 120 V. 
3.3.3.2 MS/MS analysis 
Tandem mass spectrometric analysis was conducted using an AB SCIEX QTRAP 4000 
hybrid triple quadrupole-linear ion trap mass spectrometer (QqLIT-MS) equipped with a 
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‘Turbo V Ion spray’ ESI source (AB SCIEX, Redwood City, CA, USA). Nitrogen was 
used as the collision gas for CID-MS/MS. The instrument was operated in the positive ion 
mode with an optimized declustering potential of 40 V for each compound. The collision 
energy (CE) was also optimized and set at 55 eV for C8-6-C8, 50 eV for C8-6-N and 22 eV 
for C8-6-I. The optimized CEs were sufficient to induce fragmentation while the precursor 
ion remained abundant. Subsequently, aliquots of the samples were directly infused into 
the instrument at a flow rate of 10 µL/min by using a Model 11 Plus Syringe Pump 
(Harvard Apparatus, Holliston, MA, USA). The ionspray voltage was set at 5500 V with 
the source temperature set at 200oC. 
The MS/MS analysis of each compound was also performed using the QSTAR. The 
MS/MS spectra obtained from both instruments is similar; however, the MS/MS spectra 
obtained from the QTRAP provided more information. 
3.3.3.3 Multi-stage MS3 analysis 
MS3 analysis of the selected product ions was performed on the AB SCIEX QTRAP 4000 
instrument under the same optimized conditions described above. The excitation energy 
was optimized to obtain sufficient product ions. The excitation energy ranged from 150 V 
- 190 V for C8-6-I, 130 V - 175 V for C8-6-N, and 115 V - 185 V for C8-6-C8. 
3.4 Results and Discussion 
3.4.1 Single-stage MS analysis 
The full scan ESI-QqToF-MS spectra (Figure A.1, Appendix A) of all three bifunctional 
compounds showed an abundant singly charged precursor ion [M+H]+  (C8-6-N: m/z 
425.2660; C8-6-I: m/z 410.2551; and C8-6-C8: m/z 471.2468). The exact mass measurement 
analysis revealed mass accuracies of less than 2 ppm (Table A.1, Appendix A), hence 
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confirming the expected molecular structures. These mass accuracies were comparable to 
the results obtained from previous structural work in which external calibration was 
utilized on the QSTAR system (193). 
3.4.2 MS/MS analysis 
Since all three investigated compounds contain a common backbone structure composed 
of caffeine with a six carbon alkyl linker attached through the C8 position of caffeine 
(Figure 3.2), we hypothesized that caffeine dissociation would be the driving force during 
MS/MS analysis of these bifunctional compounds; however, this was not the observed 
case. We noticed that all three bifunctional compounds have distinct fragmentation patterns 
and dissociation of the caffeine moiety is only a minor pathway in the fragmentation of C8-
6-N and C8-6-I. Interestingly, the dissociation of the caffeine moieties of C8-6-C8 required 
a high CE of 55 eV compared to the relatively low CE required for the dissociation of C8-
6-N (50 eV) and C8-6-I (22 eV). In fact, if CE of 55 eV is applied for C8-6-N and C8-6-I, 
the ion is completely depleted indicating differential stability among the bifunctional 
compounds. In other words, caffeine is more stable than nicotine and 1-aminoindan, so 
fragmentation of the nicotine and 1-aminoindan moieties is the driving force during 
MS/MS analysis of C8-6-N and C8-6-I respectively. Furthermore, the fragmentation 
pathway of C8-6-N and C8-6-I shows only a few product ions originating from caffeine 
dissociation. On the contrary, the fragmentation pathway of C8-6-C8 consists of only 
product ions originating from caffeine dissociation. This suggests to us that when 
incorporated into these bifunctional compounds, the caffeine moiety may be more stable 
to fragmentation than either the nicotine or 1-aminoindan moieties. The fragmentation of 
the nicotine and 1-aminoindan moieties occurs primarily in a saturated, unconjugated 
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region, whereas caffeine possesses more extensive conjugation. This extensive conjugation 
and accompanying resonance effects for caffeine may be responsible for attenuating 
fragmentation. Hence, in the presence of nicotine or 1-aminoindan, caffeine dissociation 
in these bifunctional compounds is minor.  
                                                                        
Figure 3.2 Backbone structure of all three bifunctional compounds. 
Furthermore, MS3 analysis (Figure A.2, Appendix A) revealed the genesis of the product 
ions observed in the MS/MS spectrum of the investigated bifunctional compounds. For 
ease of representation, the observed product ions were classified as initial product ions 
followed by ions designated as first, second, and third cohort ion groups. The first cohorts 
are product ions originating directly from the precursor ions, and subsequent dissociation 
(MS3 analysis) of some of the first cohort ions gives rise to second cohort ions. MS3 
analysis of those designated as second cohort ions gives rise to third cohort ions. However, 
product ions not found on the MS3 spectrum of the first, second, and third cohorts are called 
initial product ions.  
Moreover, the fragmentation reaction mechanism for most of the product ions involves two 
or three steps with an intermediate product ion which undergoes further dissociation to give 
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the projected product ion. The intermediate product ions are also present in the MS/MS 
spectrum.  
The following systematic method for identifying product ions is used in this study: the first 
cohort product ions are labeled with alphanumeric characters (for example A2), second 
cohort product ions with alphanumeric and numeric in superscript (for example A21), third 
cohort product ions with alphanumeric and numeric-plus sign in superscript (for example 
A21+), and those initial product ions that are not found in the MS3 spectrum of the first, 
second, and third cohort product ions are labeled with numbers (for example 1). The 
detailed tandem mass spectrometric fragmentation behaviour of these bifunctional 
compounds is described below. 
3.4.2.1 MS/MS analysis of C8-6-C8 
The MS/MS spectrum, as well as the proposed fragmentation pathway for C8-6-C8 are 
shown in Figure 3.3A and B. 
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Figure 3.3 MS/MS spectrum of C8-6-C8 (A) and the proposed fragmentation pathway 
for C8-6-C8 (B). 
B 
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The MS/MS analysis of the singly charged [M+H]+ ion of C8-6-C8 gave rise to four first 
cohort product ions with each having their distinct dissociation pathway. Product ion A1 
(m/z 427.3) is derived from a ring contraction with a NL of carbon dioxide (CO2, 44 Da). 
Interestingly, a previous study that investigated the fragmentation pattern of caffeine 
reported that a NL of acetaldehyde is associated with the ring contraction of caffeine (194). 
The loss of acetaldehyde is logical; however, our accurate mass measurement study 
suggests that the ring contraction of the caffeine moiety of C8-6-C8 is associated with a NL 
of carbon dioxide and the mass error of the corresponding product ion (A1) is 1.6384      
ppm (Table A.2, Appendix A) compared to a mass error of -85.2020 ppm for the loss of 
acetaldehyde. Therefore, we proposed a new mechanism for the loss of carbon dioxide 
from the caffeine moiety of C8-6-C8 (Figure 3.4A). In the initial step, one of the O-carbonyl 
atoms attacks the carbonyl-C to form a carbamate along with ring opening and formation 
of an aziridine as shown in Figure 3.4A. Expulsion of carbon dioxide from the aziridine-
carbamate occurs resulting in the observed product ion (A1). The theoretical mechanistic 
loss of acetaldehyde from the caffeine moiety of C8-6-C8 is shown in Figure 3.4B. Methyl 
migration to the carbonyl carbon occurs concurrently with hydrogen capture from N-CH3 
followed by bond formation between CH2 and N, as well as N-N bond formation (Figure 
3.4B). 
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Figure 3.4 The proposed mechanism for the loss of carbon dioxide from C8-6-C8 (A) 
and loss of acetaldehyde from C8-6-C8 (B). 
Product ion A2 (m/z 414.3) is the result of a retro-Diels-Alder (RDA) rearrangement with 
a NL of methyl isocyanate (O=C=NCH3, 57 Da), which is in agreement with the previously 
reported fragmentation mechanism of caffeine (194). Product ion A3 (m/z 329.4) results 
from the NL of 1, 3-dimethyl-5, 6-dihydrouracil (C6H10N2O2, 142 Da) while product ion 
A4 (m/z 221.3) arose from the NL of 8-butyl-1, 3, 7-trimethylpurine-2, 6-dione 
(C12H18N4O2, 250 Da) as shown in Figure 3.3B.  
A 
B 
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Product ions A1-A4 each undergo additional dissociation which as confirmed by MS3 
analysis (Figure A.2A, Appendix A) give second cohort product ions. A1 is further 
dissociated to form ions A11 (m/z 400.5) and A12 (m/z 398.4) due to the NL of hydrogen 
cyanide (27 Da) and methanimine (CH3N, 29 Da), respectively. The elimination of carbon 
monoxide (CO, 28 Da) from A2 (m/z 414.3) leads to the formation of A21 (m/z 386.6) while 
the ion observed at m/z 370.5 (A22) is the result of an inner ring breakage with the NL of 
carbon dioxide (CO2, 44 Da) from A2, similar to the mechanism explained in Figure 3.4A. 
On the other hand, further dissociation of A2 gives rise to the ions observed at m/z 357.3 
(A23) and m/z 304.3 (A24) through an RDA with the concomitant loss of methyl isocyanate 
(O=C=NCH3, 57 Da), and a NL of C5H6N2O (110 Da) respectively as shown in Figure 
3.3B. In the case of A3, it dissociates at the end of the linker region and caffeine moiety 
eliminating acetonitrile (CH3CN, 41 Da) to yield the ion observed at m/z 288.2 (A31).  The 
formation of A41 from A4 involves two steps: first, the rearrangement of A4 through an 
RDA reaction results in the formation of the intermediate ion at m/z 164 (7) (Figure 3.3A) 
due to the NL of methyl isocyanate (O=C=NCH3, 57 Da). This is followed by the 
elimination of carbon monoxide (CO, 28 Da) from the ion at m/z 164.0 (7) giving rise to 
the product ion at m/z 136.0 (A41) as shown in Figure 3.3B.  
Furthermore, some of the second cohort product ions undergo further dissociation to third 
cohort product ions. For example, the elimination of carbon monoxide (CO, 28 Da) from 
A22 leads to the formation of the ion (A22+) at m/z 342.5. While the loss of C6H9N3O (139 
Da) from A22 gives rise to the ion (A22++) at m/z 231.4, the ion (A22+++) at m/z 177.3 
originated from the loss of C10H15N30 (193 Da) from A22. Additionally, the loss of 
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acetonitrile (C2H3N, 41 Da) from A31 gives rise to the ion (A31+) at m/z 247.2. These losses 
are self-explanatory including repeating mechanisms and are shown in figure 3.3B. 
The following product ions were found to originate directly from the precursor ion since 
they were not observed during MS3 analysis (Figure A.2A, Appendix A). The product ion 
designated as 1 observed at m/z 439.4 is due to the NL of methanol (CH3OH, 32 Da) from 
the precursor ion (Figure 3.3B), which is in agreement with a previously reported 
fragmentation mechanism for caffeine (194). We have proposed a mechanism for the loss 
of methanol from the caffeine moiety of C8-6-C8 (Figure 3.5). In the initial step, carbonyl 
oxygen captures an adjacent N-methyl followed by the capture of hydrogen from CH3 with 
intramolecular cyclization. Furthermore, the ions labeled 2 and 3 with m/z 277.4 and 263.4 
respectively are generated from the NL of caffeine (C8H10N4O2, 194 Da) and 1-
methylcaffeine (C9H12N4O2, 208 Da) from the precursor ion respectively (Figure 3.3B).   
 
Figure 3.5 Proposed mechanism for the loss of methanol form C8-6-C8. 
The NL of methyl isocyanate (O=C=NCH3, 57 Da) from the precursor ion at m/z 471.6 
gives an intermediate product ion observed at m/z 414.3 (A2) (Figure 3.3A). The 
subsequent loss of C9H10N4O2 (206 Da) from the intermediate product ion results in the 
formation of the product ion (4) with m/z 208.2 (Figure 3.3B). In addition, the ions 
designated 5 and 6 at m/z 195.2 and m/z 168.0 are derived from the elimination of the 
backbone structure (C14H22N4O2, 278 Da) and the backbone structure containing a cyanide 
51 
 
moiety (C15H21N5O2, 303 Da), respectively, from the precursor ion (Figure 3.3B). Three 
other dissociation mechanisms, each involving a two or three -step reaction generated ions 
with m/z 164.0 (7), 151.0 (8), and 110.5 (9).  The ion (7) at m/z 164.0 is generated from the 
precursor ion at m/z 471.6 through an RDA rearrangement with the loss of methyl 
isocyanate (O=C=NCH3, 57 Da) to give an intermediate product ion at m/z 414.3 (A2) 
(Figure 3.3A) followed by the loss of 8-butyl-1, 3, 7-trimethylpurine-2, 6-dione 
(C12H18N4O2, 250 Da) as shown in Figure 3.3B. Furthermore, the ion (8) at m/z 151.0 is 
directly derived from the precursor ion through the loss of carbon dioxide (CO2, 44 Da) to 
give an intermediate product ion at m/z 427.3 (A1) (Figure 3.3A), followed by the loss of 
C14H20N4O2 (276 Da) from the intermediate product ion. The ion (9) at m/z 110.5 is 
generated from the precursor ion through an RDA rearrangement with the loss of methyl 
isocyanate (O=C=NCH3, 57 Da) to give the first intermediate product ion with m/z 414.3 
(A2) (Figure 3.3A), followed by the elimination of carbon monoxide (CO, 28 Da) to give 
a second intermediate product ion at m/z 386.6 (A21) (Figure 3.3A) and an additional loss 
of C14H20N4O2 (276 Da) as shown in Figure 3.3B. The diagnostic NLs associated with the 
dissociation of C8-6-C8 are shown in Table A.5, Appendix A. 
3.4.2.2 MS/MS analysis of C8-6-N 
The MS/MS spectrum, as well as the proposed fragmentation pathway for C8-6-N are 
shown in Figure 3.6A and B. The proposed structure of most of the product ions for C8-6-
N was confirmed using accurate mass measurement, showing a mass error of less than 9 
ppm (Table A.3, Appendix A). The fragmentation of the singly charged [M+H]+ ion of C8-
6-N gave rise to two first cohort product ions (Figure 3.6B) that emanated from the 
cleavage of the nicotine portion of C8-6-N. B1 and B2 ions with m/z 346.4 and m/z 332.4 
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resulted from the NL of pyridine (C5H5N, 79 Da) and beta-picoline (C6H7N, 93 Da) 
respectively from the precursor ion as shown in Figure 3.6B. The NL of pyridine is in 
agreement with the previously reported fragmentation mechanism of nicotine (195). 
However, the authors did not observe a neutral loss of beta-picoline from the dissociation 
of nicotine (195). This may be because the authors used a different instrument, Linear Trap 
Quadrupole-Orbitrap hybrid mass spectrometer. 
These two first cohort product ions undergo further dissociation to give second cohort 
product ions. The product ion at m/z 346.4 (B1: Figure 3.6A) gave rise to three other 
product ions at m/z 277.3 (B11), 275.3 (B12), and 207.2 (B13) (Figure 3.6A). While the ion 
(B11) at m/z 277.3 arose from the loss of 2, 3-dihydro-1H-pyrrole (C4H7N, 69 Da) from B1 
(Figure 3.6B), the ion (B12) at m/z 275.3 was derived from the loss of pyrrolidine (C4H9N, 
71 Da) from B1. Finally, the loss of 1-pentyl-2, 3-dihydropyrrole (C9H17N, 139 Da) from 
B1 yielded the product ion (B13) with m/z 207.2. The product ion at m/z 332.4 (B2) 
generated the product ion (B21) at m/z 263.2 as a result of the loss of C4H7N (69 Da), as 
shown in Figure 3.6B. 
The other observed product ions originated directly from the fragmentation of the precursor 
ion at m/z 425.3 as they were not found in the MS3 analysis (Figure A.2B, Appendix A) of 
the first, second, and third cohort product ions. The ion (1) at m/z 306.4 arose from the loss 
of 3-(1-propenyl) pyridine (C8H9N, 119 Da) from the precursor ion, while the loss of 3-(1-
ethylpyrrolidin-2-yl) pyridine (C11H16N2, 176 Da) from the precursor ion gave rise to the 
product ion (2) at m/z 249.3 (Figure 3.6B). The ion at m/z 220.4 (3) originated from a 
fragmentation reaction involving two steps: the loss of nornicotine (C9H12N2, 148 Da) from 
the precursor ion to give an intermediate product ion at m/z 277.3 (B11) (Figure 3.6A) 
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followed by the loss of methyl isocyanate (O=C=NCH3, 57 Da) through an RDA (Figure 
3.6B). The ion (4) at m/z 195.1 originated from the loss of C15H22N2 from the precursor ion 
as shown in Figure 3.6B. The other three product ions at m/z 168.2(5), 136.0(6), and 
132.0(7) were derived from the precursor ion by the loss of C16H23N3 (257 Da), 
C14H19N5O2 (289 Da), and C14H23N5O2 (293 Da), respectively. These losses are shown in 
Figure 3.6B. It is interesting to note that only (3) and (5) are derived from dissociation of 
caffeine, indicating that nicotine is the driving force in the dissociation of C8-6-N. 
Furthermore, the ion (8) at m/z 130.0 was generated through a two-step process: loss of 
C14H23N5O2 (293 Da) from the precursor ion to generate an intermediate ion with m/z 132.0 
(7) (Figure 3.6A) followed by the loss of molecular hydrogen (H2, 2 Da) from the 
intermediate product ion (Figure 3.6B). Meanwhile, the major product ion (9) at m/z 120.0 
(Figure 3.6A) was derived from the precursor ion by the loss of C15H23N5O2 (305 Da) while 
the ion (10) at m/z 110.5 originated from a two-step reaction involving the loss of pyridine 
(C5H5N, 79 Da) from the precursor ion to form an intermediate product ion at m/z 346.4 
(B1) (Figure 3.6A) followed by the loss of 1, 3, 7-trimethyl-8-propylpurine-2, 6-dione 
(C11H16N4O2, 236 Da) from the intermediate product ion as shown in Figure 3.6B. The loss 
of C16H25N5O2 (319 Da) from the precursor ion gives rise to the product ion at m/z 106.0 
(11). In agreement with our results, the product ions with m/z 132.0 (7), 130.0 (8), 120.0 
(9), and 106.0 (11) (Figure 3.6A) have all been previously reported for the fragmentation 
of nicotine (195). The diagnostic NLs associated with the dissociation of C8-6-N are shown 
in Table A.5, Appendix A. 
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Figure 3.6 MS/MS spectrum of C8-6-N (A) and the proposed fragmentation pathway 
for C8-6-N (B). 
3.4.2.3 MS/MS analysis of C8-6-I 
The MS/MS spectrum, as well as the proposed fragmentation pathway for C8-6-I, are 
shown in Figure 3.7A and B. The fragmentation of the singly charged [M+H]+ ion of C8-
B 
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6-I gave rise to one first cohort product ion at m/z 294.4(C1) through the loss of an indene 
(C9H8, 116 Da) as shown in Figure 3.7B.  
MS3 analysis (Figure A.3A, Appendix A) of the product ion at m/z 294.4 (C1) revealed 
further dissociation to second cohort product ions. C1 underwent additional dissociation 
with a NL of ammonia (NH3, 17 Da), methylamine (CH3NH2, 31 Da), and methyl 
isocyanate (O=C=NCH3, 57 Da) giving rise to the following second cohort product ions at 
m/z 277.2 (C11), m/z 263.2 (C12), and m/z 237.3 (C13) respectively as shown in Figure 
3.7B. Interestingly, these product ions were not observed in the MS/MS analysis of C8-6-I 
(Figure 3.7A).  
Furthermore, MS3 analysis of C11 (Figure A.3B, Appendix A) indicates that subsequent 
dissociation of C11 is associated with the formation of the product ions at: m/z 168.2 
(C11+++ : loss of 6-heptenitrile, C7H11N, 109.2 Da); m/z 207.1 (C11++ : loss of 1-pentene, 
C5H10, 70.2 Da); and m/z 221.1 (C11+ :loss of 2-butene, C4H8, 56.3 Da).  
The product ion at m/z 117.0 (1) (protonated indene) originated directly from the precursor 
ion as it was not found in the MS3 analysis (Figure A.2C, Appendix A). The ion designated 
1 was generated by the loss of C14H23N5O2 (293 Da) from the precursor ion, and this 
product ion has previously been reported for the fragmentation of 1-aminoindan (196). The 
mass error of the MS/MS product ions of C8-6-I is less than 5 ppm (Table A.4, Appendix 
A); however, QqToF-MS/MS analysis did not show the product ion at m/z 117.0 (1). The 
diagnostic NLs associated with the dissociation of C8-6-I are shown in Table A.5, 
Appendix A. 
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Figure 3.7 MS/MS spectrum of C8-6-I (A) and the proposed fragmentation pathway 
for C8-6-I (B). 
3.5 Conclusion 
In this study, we evaluated the CID-MS/MS fragmentation pattern of three novel 
bifunctional compounds for PD using ESI-QqToF-MS and ESI-QqLIT-MS/MS in the 
positive ion mode. Accurate mass measurement confirmed the molecular structure of the 
tested bifunctional compounds with a mass error of less than 2 ppm (Table A.1, Appendix 
A). Given that all three tested bifunctional compounds have a common scaffold consisting 
of caffeine linked to a six carbon alkyl chain through the C8 position of caffeine (C8-6), it 
was expected that the dissociation of caffeine moiety would be the driving force in the 
fragmentation of C8-6-C8, C8-6-N, and C8-6-I; however, this was not consistent with our 
findings. We observed that all three bifunctional compounds have distinct fragmentation 
B 
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patterns and the dissociation of caffeine moiety is only a minor pathway in the 
fragmentation of C8-6-N and C8-6-I. This suggests to us that when incorporated into these 
bifunctional compounds, the caffeine moiety may be more stable to fragmentation than 
either the nicotine or 1-aminoindan moieties. The fragmentation of the nicotine and 1-
aminoindan moieties occurs primarily in a saturated, unconjugated region, whereas 
caffeine possesses more extensive conjugation. This extensive conjugation and 
accompanying resonance effects for caffeine may be responsible for attenuating 
fragmentation. Hence, in the presence of nicotine or 1-aminoindan, caffeine dissociation 
in these bifunctional compounds is minor.  
A significant observation in the fragmentation of C8-6-C8 suggests that a previously 
reported loss of acetaldehyde during caffeine fragmentation (194) is instead a loss of CO2. 
Through accurate mass measurement we observed that the ring contraction of the caffeine 
moiety of C8-6-C8 is associated with a NL of carbon dioxide, and the mass error of the 
corresponding product ion (A1) is 1.6384 ppm (Table A.2, Appendix A) compared to a 
mass error of -85.2020 ppm for the loss of acetaldehyde. We proposed a new mechanism 
for the loss of carbon dioxide from the caffeine moiety of C8-6-C8 (Figure 3.4A). 
Finally, diagnostic product ions (Figure A.2, Appendix A) and distinct NLs (Table A.5, 
Appendix A) were observed for all three tested bifunctional compounds. While the second 
and third cohort product ions are potential ions for MRM3 methods for targeted 
quantification, the diagnostic NLs can be used for targeted identification of these 
bifunctional compounds in biological matrices.  
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4.1 Abstract 
The development of disease-modifying drugs and differential diagnostic agents are the 
main focus of research in Parkinson's disease (PD). Alpha-synuclein (AS) has been 
identified as a druggable target for the development of disease-modifying drugs and 
differential diagnostic agents for PD. Recently, we reported that two bifunctional 
compounds comprised of a caffeine scaffold attached to 1-aminoindan (C8-6-I) and 
nicotine (C8-6-N) are promising candidates in preventing the pathological pathway that 
leads to PD. We also observed that caffeine linked to caffeine (C8-6-C8) did not show any 
therapeutic potential, but displayed the strongest binding to AS and may be suitable for 
development as a diagnostic agent for PD. To better understand the in vivo properties of 
these compounds we are interested in preparing their 18F labeled positron emission 
tomography (PET) imaging probes, but prior to developing these probes, it is imperative 
that we assess the in vitro metabolism of the bifunctional compounds. We investigated the 
in vitro metabolic profile of C8-6-C8, C8-6-I, and C8-6-N in human, mouse, and rat liver 
microsomes (HLM, MLM, and RLM) in parallel with positive and negative controls. 
Metabolites were identified and confirmed with accurate mass measurement and tandem 
mass spectrometry using liquid chromatography coupled with quadrupole/time of flight 
spectrometry (LC-QToF). While the caffeine scaffold in C8-6-N, C8-6-I, and C8-6-C8 was 
metabolically stable, the nicotine and 1-aminoindan moieties were either cleaved off 
(dealkylation) or hydroxylated in HLM, MLM, and RLM. This suggests that the caffeine 
moiety may be the preferable spot for the inclusion of 18F radioisotope in these bifunctional 
compounds. Dealkylation and hydroxylation are the major metabolic pathways for C8-6-I 
and C8-6-N in HLM, MLM, and RLM. Given the similarity in the metabolic pathways, 
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mouse and rat may be useful surrogates for future animal studies of C8-6-I, C8-6-N, and 
C8-6-C8.   
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4.2 Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder that is characterized by the 
misfolding and aggregation of alpha-synuclein (AS) into fibrils, and the subsequent 
inclusion of the fibrils into cytoplasmic bodies known as Lewy bodies (4, 197-199). In 
addition to the challenges associated with the accurate diagnosis of PD (39, 42, 43, 174, 
200-202), there is currently no cure for PD. Therefore, the development of disease-
modifying drugs and differential diagnostic agents are the major focus of research in PD.  
Given its role in the pathophysiology of PD, AS may be a druggable target for the 
development of disease-modifying drugs and differential diagnostic probes for PD. In view 
of this new evidence, our laboratory has focused on developing novel compounds that can 
interact with AS and prevent the pathological pathway that leads to PD. Previous studies 
suggest that caffeine, nicotine, metformin, and 1-aminoindan may be neuroprotective (127-
137). Recently, we confirmed that caffeine, nicotine, metformin, and 1-aminoindan exert 
their neuroprotective effects by binding to AS and preventing the initial misfolding 
pathway that leads to PD (32). To improve the efficacy of these compounds, we 
synthesized novel bifunctional compounds from a caffeine scaffold attached to 1-
aminoindan (C8-6-I), nicotine (C8-6-N), and caffeine (C8-6-C8) (Figure 4.1) and 
determined their ability to bind to AS and prevent AS mediated toxicity in a yeast model 
of PD (123). The study concluded that C8-6-I and C8-6-N were the most promising 
candidates for preventing AS mediated toxicity in a yeast model of PD. Although C8-6-C8 
did not show any therapeutic potential, it displayed the strongest binding to AS. In order to 
better understand the biodistribution of C8-6-I, C8-6-N and C8-6-C8 in vivo, we are 
developing methods to label the bifunctional compounds with 18F to use in positron 
emission tomography (PET) imaging studies.   
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Figure 4.1 Structure of novel bifunctional compounds. 
To develop these bifunctional compounds as therapeutics or diagnostics for PD, it is of 
great importance to determine their metabolic stability at this early stage of drug discovery 
and development. This initial drug metabolism studies serve as an appropriate screening 
mechanism to characterize drug metabolites, elucidate their metabolic pathways, and make 
suggestions for further in vivo studies with the overall goal of improving the safety and 
efficacy of these new chemical entities (NCEs) (203). Additionally, metabolism studies 
will provide useful information about metabolically stable locations to incorporate 18F on 
the bifunctional compounds.  
The liver is the major organ that is responsible for the metabolism of drugs and it contains 
drug metabolizing enzymes such as cytochrome P450 (P450) which mediates the 
oxidation, reduction, and hydrolysis (phase I) of drugs, as well as cytosolic enzymes which 
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catalyze several conjugation reactions such as glucuronidation, methylation, and 
sulfonation. Microsomes are one of the commonly used in vitro models for performing 
drug metabolism studies because they are rich in drug metabolizing enzymes (mainly 
P450) and are also economical. Another advantage of using microsomes as an in vitro drug 
metabolism model is the ability to focus on generating sufficient amount of presumptive 
P450-mediated phase I metabolites without interference from other competing processes 
such as phase II metabolism and transporter-mediated processes (204).  
Liquid chromatography coupled with mass spectrometry (LC-MS) is an important 
analytical platform for the separation, detection, identification, and structural elucidation 
of metabolites. The identification and structural elucidation of metabolites using LC-MS is 
achieved through accurate mass measurement and tandem mass spectrometry. Therefore, 
it is essential to develop an LC method as well as a mass spectrometric method for NCEs 
in preparation for future preclinical studies. Recently, we established a tandem mass 
spectrometric fingerprint for C8-6-C8, C8-6-I, and C8-6-N for future development of 
qualitative and quantitative methods (manuscript in preparation). 
The overall goal of this present study is to determine the metabolic profile of C8-6-C8, C8-
6-I, and C8-6-N in human, mouse, and rat liver microsomes (HLM, MLM, and RLM). This 
is the first preclinical study to establish the metabolic profile of C8-6-C8, C8-6-I, and C8-6-
N in HLM, MLM, and RLM. The information obtained from this study will contribute to 
the development of these bifunctional compounds as therapeutic or diagnostic agents for 
PD. 
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4.3 Materials and methods 
4.3.1 Chemicals and standards 
C8-6-N, C8-6-I, and C8-6-C8 were synthesized according to a previously established 
protocol in our laboratory (123) while 2, 2-di-(3-methoxy methyl phenyl) 1, 3-propanediol 
(MMPPD) was provided by Kevin Allen. Acetonitrile (HPLC grade purity), methanol 
(HPLC grade purity), chloroform, formic acid (LC/MS grade purity), magnesium chloride 
(MgCl2) were purchased from Fisher Scientific (Fairlawn, NJ) while water was filtered 
using a Millipore, MilliQ system with a Quantum EX cartridge (Mississauga, ON). The 
following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): sodium 
pyrophosphate decahydrate (SPP), chlorzoxazone, and dipotassium orthophosphate 
(K2HPO4). Potassium dihydrogen orthophosphate (KH2P04) was purchased from BDH 
Chemicals (Toronto, ON) while reduced nicotinamide adenine dinucleotide (NADPH) was 
purchased from Roche Diagnostics (Indianapolis, IN). HLM, MLM, and RLM were 
purchased from Invitrogen (Life Technologies; Burlington, ON). 
4.3.2 Microsomal incubation 
A standard method for in vitro metabolism of novel bifunctional compounds using liver 
microsomes was developed and optimized in our laboratory. This method included 
incubation of chlorzoxazone as a positive control to determine the viability of the liver 
microsomes. The incubation mixture contained 5 mM MgCl2, 10 mM SPP, 0.5 mg/mL 
liver microsomes (RLM, MLM and HLM), and 30 μM test compound. After 5-minute pre-
incubation in a shaking water bath at 37oC, 10 μL NADPH (1 mM final concentration) in 
pH 7.4 100 mM potassium phosphate buffer was added to initiate the reaction. The 
incubation mixtures were prepared in duplicate in parallel with two negative controls. The 
first negative control did not contain NADPH while the second negative control excluded 
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active liver microsomes. The reaction was terminated after 60 minutes by the addition of 
200 μL of ice-cold acetonitrile containing 50 μM MMPPD as an internal standard. 
The samples were vortexed for about 1 min and then centrifuged at 14000×g for 10 
minutes. Subsequently, 200 µL of the supernatant was placed in an LC vial, and 50 µL 
were injected into the LC-QqToF instrument. 
4.3.3 Non-targeted metabolite identification 
The analysis of incubated samples was performed on an Agilent 1100 high-performance 
liquid chromatography (HPLC) (Agilent technologies; Mississauga, ON) coupled with an 
AB SCIEX QSTAR XL quadrupole orthogonal time-of-flight hybrid mass spectrometer 
(QqToF-MS) equipped with an electrospray ionization (ESI) source (AB SCIEX, Redwood 
City, CA, USA). The Agilent 1100 series HPLC was equipped with a degasser (G1379A), 
binary pump (G1312A), autosampler (G1329A), and diode array detector (G1315B), and 
the HPLC column was an Agilent Poroshell 120 EC-C18 column (4.6 ×50 mm, 2.7 µm). 
The binary solvent system used consisted of 0.1% LC-MS grade formic acid in water 
(mobile phase A) and 0.1% LC-MS grade formic acid in acetonitrile (mobile phase B), 
with a flow rate of 0.3 mL/min. A 20-minute gradient elution was set up to ensure 
separation of the metabolites and parent compounds. The gradient was programmed to start 
with an initial isocratic hold at 90% mobile phase A for 5 minutes, decreasing gradually to 
10% mobile phase A and holding for 10 minutes before returning to the initial conditions 
at 21 minutes and equilibrating for 5 minutes. The mass spectrometer was operated in the 
positive ion mode, and nitrogen was used as the ESI nebulizing and drying gas. The 
instrument was calibrated with a two-point external calibration using cesium iodide (CsI, 
m/z 132.9049, Sigma-Aldrich, Oakville, ON, Canada) and sex pheromone inhibitor 
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iPD1(m/z 829.5393, Bachem Bioscience Inc., PA, USA). The ion source voltage was set 
at 5500 V while the source temperature was optimized and set at 400oC. The declustering 
potential and focusing potential was set at 40 V and 120 V respectively. A scan range of 
100-700 m/z was used for metabolite detection.  
Identification of metabolites was made by observing unique peaks present in the reaction 
mixture samples in comparison to the negative control samples. Confirmation of metabolite 
structure was carried out using accurate mass measurement and tandem mass spectrometry. 
Tandem mass spectrometric analysis of the observed metabolite ions was performed under 
the same conditions and set to target the tentative metabolite ions and retention times in 
order to confirm their fragmentation pattern. The collision energy was optimized and was 
set at 25 eV (C8-6-N), and 17 eV (C8-6-I) to ensure sufficient fragmentation without 
depleting the precursor ion. Data analysis was done using Analyst QS 1.1. 
Liquid-liquid extraction consisting of a mixture of chloroform-isopropanol (85:15, v/v) 
was previously used by Grant et al., (143) for extraction of caffeine and its metabolites 
from HLM. Therefore, we evaluated this mixture of solvents for extracting C8-6-C8, C8-6-
N, and C8-6-I, as well as their corresponding metabolites from HLM, MLM, and RLM but 
found unacceptably high variation in the results. The variation with acetonitrile was 
acceptable and was selected as the solvent for protein precipitation. 
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4.4 Results and Discussion 
4.4.1 Metabolite profiling 
The determination of the major metabolic pathway of NCEs can provide useful information 
about its route of elimination from the body, and such information can be used in further 
structural optimization. Additionally, the biotransformation of PET imaging probes can 
alter the information obtained from biodistribution studies; therefore, it is important to 
perform metabolism studies of NCEs to determine the least metabolically labile spot for 
the attachment of a radioisotope as a guide for the development of novel PET imaging 
probes.  
The goal of this study is to determine the metabolic fate of C8-6-N, C8-6-I, and C8-6-C8 in 
HLM, MLM, and RLM. This metabolism studies addressed three major questions: are C8-
6-N, C8-6-I, and C8-6-C8 metabolized in HLM, MLM, and RLM; are the metabolic 
pathways of C8-6-N, C8-6-I, and C8-6-C8 the same in HLM, MLM and RLM; and what are 
the least metabolically labile positions for the inclusion of 18F in C8-6-N, C8-6-I, and C8-6-
C8.  
Herein, we demonstrate the importance of combining accurate mass measurement and 
tandem mass spectrometric analysis in the identification and structural elucidation of the 
major presumptive P450 metabolites for C8-6-N, C8-6-I, and C8-6-C8 in HLM, MLM, and 
RLM. First, we confirmed the conversion of chlorzoxazone to 6-hydroxychlorzoxazone as 
an indication of microsomal viability. Subsequently, potential metabolites of the 
bifunctional compounds were selected by comparing the chromatograms of the reaction 
mixtures against those of the negative control samples (No NADPH and inactive liver 
microsomes) as shown in Figure 4.2. The negative control samples did not contain either 
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NADPH or active liver microsomes therefore, they would not metabolize the bifunctional 
compounds. 
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Figure 4.2 Total ion chromatogram (ESI in positive mode) of LC-MS analysis of a 50 
L injection of 15 M samples from in vitro mouse liver microsomal metabolism of 
C8-6-I (A), C8-6-N (B), and C8-6-C8 (C). 
B 
C 
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Two metabolites (M1 and M2) were identified for C8-6-I (Figure 4.2A), and two 
metabolites M3 and M4 were identified for C8-6-N (Figure 4.2B). On the contrary, no 
metabolite was detected for C8-6-C8 (Figure 4.2C) in HLM, MLM, and RLM. We also 
observed that C8-6-N undergoes extensive metabolism in HLM, MLM, and RLM as the 
parent compound was not detected in the reaction mixture after 60 minutes incubation 
(Figure 4.2B).  
The metabolites were first identified using accurate mass measurement, and the mass error 
of each of the identified metabolites was less than 7 ppm (Table B.1, Appendix B), 
confirming the molecular structures. These mass accuracies were comparable to the results 
obtained from previous structural work in which external calibration was used (see chapter 
3).  
Furthermore, MS/MS analysis was performed to confirm the molecular structures of the 
identified metabolites and to examine how the fragmentation pattern of the identified 
metabolites relate to the previously established mass spectrometric pattern of C8-6-N, C8-
6-I, and C8-6-C8 as described in chapter 3.4.2. 
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Figure 4.3 The ESI-QToF-MS/MS spectrum for M1(A), M2(C), M4(E), and the 
proposed fragmentation pathway for M1(B), M2(D), M4(F). ESI was performed in 
positive mode. 
The MS/MS spectrum of M1 (Figure 4.3A) revealed a diagnostic product ion with m/z 
277.1643 (M11) produced by the neutral loss of ammonia (17 Da) from the terminal amino 
F 
E 
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group of the precursor ion at m/z 294.1893 (Figure 4.3B). This fragmentation pattern 
correlates with the previously established fragmentation pathway for C8-6-I in which 
fragmentation of C8-6-I leads to the formation of the product ion with m/z 294.4, and 
subsequent fragmentation of this product ion (m/z 294.4) leads to the generation of the 
diagnostic product ion at m/z 277.4 with the concomitant loss of ammonia (see chapter 
3.4.2.3). More so, accurate mass measurement revealed that the molecular formula of M1 
is C14H24N502 with a mass error of 0.000 ppm (Table B.1, Appendix B) which correlates 
with the proposed molecular structure of M1. Together the results obtained from the 
tandem mass spectrometric analysis and accurate mass measurement clearly confirmed the 
molecular structure of M1. 
Metabolite M2 is 16 Da higher than the parent compound (C8-6-I) consistent with the 
formation of a hydroxylated metabolite of C8-6-I. The MS/MS spectrum (Figure 4.3C) of 
the precursor ion with m/z 426.2539 revealed an abundant diagnostic product ion at m/z 
408.2374 (M21) corresponding to the loss of a water molecule (18 Da; Figure 4.3D) from 
the precursor ion, in agreement with the presence of a hydroxyl group on the precursor ion. 
The product ion with m/z 294.1917 (M22) is also diagnostic for the parent compound (C8-
6-I) (see chapter 3.4.2.3), indicating that the precursor ion [M2+H]+ originated from C8-6-
I. M22 is formed from the loss of hydroxyindan from the precursor ion [M2+H]+ suggesting 
that the hydroxyl group is located on the indan moiety of M2 (Figure 4.3D). The neutral 
loss of C14H23N5O2 (293 Da) from [M2+H]
+ is associated with the formation of the product 
ion at m/z 133.0583 (M23) as shown in Figure 4.3D. A neutral loss of C14H23N5O2 (293 
Da) from C8-6-I is associated with the formation of a protonated indene (see chapter 
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3.4.2.3) and the protonated indene formed from this loss is only 16 Da higher than M23 
strongly indicating that the hydroxyl group is located on the indan moiety of M2.  
Although the fragmentation pattern suggests that the hydroxyl group is located on the indan 
moiety of M2, it does not indicate the position in which it is located on the indan moiety. 
However, previous studies suggest that rasagiline (an antiparkinson drug) undergoes P450 
mediated biotransformation to 1-aminoindan, and subsequent P450 mediated metabolism 
of 1-aminoindan leads to the formation of 3-hydroxy-1-aminoindan (161-163). This 
suggests that position 3 of the indan may be the location of the hydroxyl group on M2; 
however, further structural characterization studies will be necessary for the determination 
of the position of the hydroxyl group on the indan moiety of M2. Furthermore, accurate 
mass measurement revealed the molecular formula of M2 as C23H32N5O3 with a mass error 
of 6.8035 ppm (Table B.1, Appendix B), confirming the projected molecular structure.   
The M3 metabolite of C8-6-N has a similar fragmentation pathway as the M1 metabolite 
of C8-6-I. The molecular formula and mass error of M1 and M3 are the same indicating 
that they both have the same molecular structure.  
More so, M4 is 16 Da higher than the parent compound (C8-6-N) indicating hydroxylation. 
Furthermore, the MS/MS spectrum of M4 (Figure 4.3E) shows an abundant diagnostic 
product ion at m/z 423.2557 (M41) originating from the neutral loss of water molecule from 
the precursor ion at m/z 441.2713 [M4+H]+ (Figure 4.3F) indicating the presence of a 
hydroxyl group on the precursor ion [M4+H]+. Subsequent fragmentation of [M4+H]+ is 
linked to the neutral loss of C9H12N2O (164 Da) with the concomitant formation of the 
diagnostic product ion at m/z 277.1667 (M42) (Figure 4.3F). The diagnostic neutral loss of 
C9H12N2O (164 Da) suggests that the hydroxyl group is located on the nicotine moiety of 
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the M4. Additionally, M42 is one of the product ions of C8-6-N, and its presence in the 
MS/MS spectrum of M4 suggests that M4 originated from C8-6-N. The diagnostic product 
ion at m/z 148.0783 (M43) is formed from the loss of C14H23N5O2 (293 Da; Figure 4.3F) 
from the precursor ion at m/z 441.2713 (Figure 4.3E). The presence of a hydroxyl group 
on M43 strongly suggest that the hydroxyl group is located on the nicotine moiety of M4.  
Interestingly, 2' and 5' phase I hydroxylated metabolites of nicotine have been reported 
(156, 205-207). This suggests that the 2' or 5' position of nicotine may be the location onto 
which the hydroxyl group is attached on M4; however, it is essential to conduct further 
structural characterization studies to determine the exact position in which the hydroxyl 
group is located on M4. Furthermore, accurate mass measurement revealed the molecular 
formula of M4 as C23H33N6O3 with a mass error of 6.1188 ppm (Table B.1, Appendix B), 
confirming the projected molecular structure.   
4.4.2 Metabolic pathway 
Two metabolic pathways were observed in HLM, MLM and RLM for each of C8-6-I 
(dealkylation (M1) and hydroxylation (M2), Figure 4.4A) and C8-6-N (dealkylation (M3) 
and hydroxylation (M4), Figure 4.4B). In contrast, no metabolite was detected for C8-6-C8 
in HLM, MLM, and RLM (Figure 4.4C). Given that C8-6-N, C8-6-I, and C8-6-C8 have the 
same metabolic pathway in HLM, RLM, and MLM, mouse and rat may be useful models 
for future animal studies of these bifunctional compounds.  
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Figure 4.4 The proposed metabolic pathway for C8-6-I (A), C8-6-N (B), and C8-6-C8 
(C) in human, mouse, and rat liver microsomes. 
B 
C 
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Given that C8-6-N, C8-6-I, and C8-6-C8 all have a common caffeine backbone structure, we 
expected that caffeine metabolism would be the common metabolic pathway for these 
bifunctional compounds; however, this was not the case. We observed that the caffeine 
moiety of these bifunctional compounds was conserved as no metabolite corresponding to 
the phase I biotransformation pathway of caffeine was observed. In fact, the conservation 
of the caffeine moiety was confirmed in C8-6-C8 as no corresponding metabolite was 
observed in HLM, MLM, and RLM. Interestingly, previous in vitro metabolism studies 
indicate that caffeine undergoes phase 1 metabolism to generate four primary metabolites: 
paraxanthine, theobromine, theophylline, and 1, 3, 7-trimethyluric acid which correspond 
to N3, N1, N7- demethylation, and C8-oxidation respectively (143, 208-210); however, 
none of these metabolites were observed for all investigated bifunctional compounds.  
We speculate that dimerization of the caffeine monomer might have conferred energetic 
stability to C8-6-C8 hence making it metabolically stable to P450 metabolism. In fact, our 
tandem mass spectrometric analysis confirmed the energetic stability of C8-6-C8 as more 
collision energy was required for complete dissociation of C8-6-C8 compared to C8-6-N 
and C8-6-I (manuscript in preparation). Additionally, the low in vitro turnover rate of the 
enzymes involved in the metabolism of caffeine (143, 211) may be responsible for the 
metabolic stability of C8-6-C8, as well as the caffeine moiety of C8-6-I and C8-6-N.  
Intriguingly, Istradefylline, which is a caffeine analogue that is currently under 
development for treatment of the signs and symptoms of PD, was reported to be primarily 
eliminated by oxidative metabolism on the non-caffeine moiety, with the main metabolites 
(Figure 4.5) being M1 (4′‐O‐monodesmethylated) and M8 (1‐β‐hydroxylated) (data on file; 
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Kyowa Kirin Pharmaceutical Development, Inc.) suggesting that C8 functionalization of 
caffeine may confer metabolic stability.  
Furthermore, we previously observed that C8-6-C8 did not protect yeast cells and may have 
been toxic, even though caffeine was found to prevent AS mediated toxicity in a yeast 
model of PD (123). Whether toxicity is the result of a lack of P450 metabolism leading to 
diminished clearance of C8-6-C8 is unknown.   
 
Figure 4.5 Primary phase I metabolic pathway of Istradefylline. 
The 1-aminoindan moiety of C8-6-I is a P450 metabolite of the antiparkinson drug, 
rasagiline which can be further metabolized to 3-hydroxy-1-aminoindan (161-163). 
Interestingly, we identified a hydroxylated metabolite of C8-6-I and tandem mass 
spectrometric analysis suggests that the hydroxyl group is located on the 1-aminoindan 
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moiety; however, it is not clear as to the position in which the hydroxyl group is located 
on the 1-aminoindan moiety. We proposed a reaction mechanism for the dealkylation and 
hydroxylation of C8-6-I (Figure 4.6). For the dealkylation reaction, we proposed an initial 
hydroxylation at the 1-position followed by a breakdown of the carbinolamine to form M1 
with the concomitant loss of 1-oxoindan (Figure 4.6A), while the hydroxylation of C8-6-I 
is more likely to occur at the benzylic 3-position to give M2 (Figure 4.6B). It has been 
suggested that 3-hydroxy-1-aminoindan may have neuroprotective effects (168); therefore 
M2 may also be neuroprotective. Additionally, given that M1 still contains the caffeine 
moiety, it may also have neuroprotective properties. 
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Figure 4.6 Proposed mechanism for dealkylation (A) and hydroxylation (B) of C8-6-I 
in human, mouse, and rat liver microsomes. 
 Nicotine undergoes in vitro P450-mediated metabolism resulting in the following 
metabolites: nicotine-Δ 1′ (5′) -iminium ion, 5'-hydroxynicotine, nornicotine, 2'-
hydroxynicotine, 4-(methylamino)-1-(3- pyridyl)-1-butanone, 4-oxo-4-(3-pyridyl) 
butanoic acid and 4- hydroxy-4-(3-pyridyl) butanoic acid (148). We identified a 
hydroxylated metabolite (M4) for C8-6-N, and tandem mass spectrometric analysis 
suggests that the hydroxyl group is located on the nicotine portion of C8-6-N. Given 
that 70-80% of nicotine is biotransformed to cotinine and the 5'-hydroxylation pathway 
ultimately leads to the formation of cotinine by a cytoplasmic aldehyde oxidase-
mediated reaction (148), we propose that the hydroxyl group on M4 is located on the 
5'-position of the nicotine moiety (Figure 4.7B). Since microsomes do not contain 
cytoplasmic enzymes such as aldehyde oxidase, the 5'-hydroxylated metabolite cannot 
be converted to cotinine. We propose that the mechanism of formation of M3 is based 
on ring opening dealkylation which occurs at the 2'-hydroxy position followed by 
dealkylation at the 5'-hydroxy position resulting in loss of 4-oxo-4-pyridyl butanal (Figure 
4.7A).  
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Figure 4.7 Proposed mechanism for dealkylation (A) and hydroxylation (B) of C8-6-
N in human, mouse, and rat liver microsomes. 
In order for these novel bifunctional compounds to be developed as imaging probes with 
clinical translation for diagnosis of PD, they will be required to display high binding 
affinity to AS, high specificity to AS, high sensitivity, high contrast ratio, high in vivo 
B 
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stability, low immunogenicity and toxicity (96). The metabolic stability of these 
compounds can alter their binding affinity, sensitivity, selectivity, and toxicity; 
however, the in vitro metabolism studies suggest that the caffeine scaffold of these 
bifunctional agents is stable and may be the optimal location for the attachment of the 
18F radioisotope. 
This in vitro metabolism study serves as an initial screening mechanism to rule out any 
insignificant metabolic pathways and further direct in vivo testing (203). Certain 
factors for in vivo testing that are not accounted for in this study include the absence 
of cytosolic enzymes and cofactors to support the generation of phase II metabolites, 
as well as xenobiotic transporters.   
4.5 Conclusion 
In this study, we evaluated the metabolic stability of C8-6-N, C8-6-I, and C8-6-C8 in 
HLM, MLM, and RLM. Accurate mass measurement and tandem mass spectrometry 
were used to identify and elucidate the structure of the corresponding metabolites of 
C8-6-N, C8-6-I, and C8-6-C8 in HLM, MLM, and RLM. The caffeine moiety of all of the 
tested compounds was stable to in vitro Phase 1 metabolism, whereas the nicotine and 
aminoindan moieties underwent hydroxylation, presumably as a result of cytochrome 
P450 mediated metabolism. The same metabolites were observed for C8-6-I and C8-6-
N in HLM, MLM, and RLM, suggesting that mouse and rat may be useful surrogates for 
future animal studies of these bifunctional compounds. These results suggest that 
placement of the 18F radioisotope should be on the caffeine moiety of C8-6-I, C8-6-N, and 
C8-6-C8. 
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5.0 Chapter Five: Bioanalytical Method Development and Validation for 
the Quantitative Determination of Novel Bifunctional Compounds in 
Human, Mouse, and Rat Liver Microsomes. 
5.1 Introduction 
The development of disease-modifying drugs and differential diagnostic agents are the 
main focus of research in Parkinson’s disease (PD). Alpha-synuclein (AS) has been 
identified as a putative target for the development of disease-modifying drugs a nd 
differential diagnostic agents for PD. Recently, we reported that novel bifunctional 
compounds comprised of a caffeine scaffold attached to nicotine (C8-6-N) and 1-
aminoindan (C8-6-I) were the most promising candidates in preventing AS mediated 
toxicity in a yeast model of  PD (123). Additionally, caffeine linked to caffeine (C8-6-C8) 
did not show any therapeutic potentials, but it demonstrated the strongest binding to AS 
making it a good candidate for the development of positron emission tomography (PET) 
imaging probe. In order to better understand the in vivo biodistribution of C8-6-I, C8-6-N, 
and C8-6-C8, we are developing methods to label the bifunctional compounds with 
18F to 
use in PET imaging studies.   
To develop these bifunctional compounds as therapeutics or diagnostics for PD, it will be 
necessary to conduct further preclinical studies to determine their safety and efficacy. To 
achieve this goal, we established a novel tandem mass spectrometric fingerprint for C8-6-
N, C8-6-I, and C8-6-C8 for future application in qualitative and quantitative analysis of these 
bifunctional compounds in biological matrices (manuscript in preparation). Interestingly, 
we applied the established mass spectrometric pattern to the identification of the 
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metabolites of C8-6-N, C8-6-I, and C8-6-C8 in human, mouse, and rat liver microsomes 
(HLM, MLM, and RLM; manuscript in preparation).  
It is important to determine the kinetics of the biotransformation of C8-6-N, C8-6-I, and C8-
6-C8 in HLM, MLM, and RLM. The evaluation of the enzyme kinetics of these bifunctional 
compounds is beneficial for further understanding of their safety and efficacy. The 
metabolite formation approach has been used for the determination of the enzyme kinetics 
and pharmacokinetic parameters of NCEs (212). The major disadvantage associated with 
this approach is the need for authentic metabolite standards which are rarely available for 
NCEs whose corresponding metabolites have not been characterized. To circumvent this 
problem, the substrate depletion approach was adopted because this method does not 
require metabolite quantification (213-215) rather substrate depletion is monitored over 
time. 
An appropriate analytical method is required for the quantification of NCEs in biological 
matrices. It is also important to validate the bioanalytical method according to stipulated 
regulatory guidelines. The goal of this research is to develop and validate a high-
performance liquid chromatography (HPLC) ultraviolet detection method for the 
quantification of C8-6-N, C8-6-I, and C8-6-C8 in HLM, MLM, and RLM. The validated 
bioanalytical method will be applied to future quantification of C8-6-N, C8-6-I, and C8-6-
C8 in HLM, MLM, and RLM for the determination of the associated metabolism kinetics. 
5.2 Materials 
C8-6-N, C8-6-I, and C8-6-C8 were synthesized according to a previously established 
protocol in our laboratory (123). Acetonitrile (HPLC grade purity), methanol (HPLC grade 
purity), chloroform, formic acid (LC-MS grade purity), magnesium chloride (MgCl2) were 
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purchased from Fisher Scientific (Fairlawn, NJ) while water was filtered using a Millipore, 
MilliQ system with a Quantum EX cartridge (Mississauga, ON). The following chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO): Sodium pyrophosphate decahydrate 
(SPP), and dipotassium orthophosphate (K2HPO4). Potassium dihydrogen orthophosphate 
(KH2P04) was purchased from BDH Chemicals (Toronto, ON) while HLM, MLM, and 
RLM were purchased from Invitrogen (Life Technologies; Burlington, ON). 
5.3 Methods 
5.3.1 Chromatographic conditions 
HPLC analysis was performed using an Agilent 1200 series HPLC (Agilent Technologies; 
Mississauga, ON) equipped with an online degasser (G1322A), quaternary pump 
(G1311A), autosampler (G1329A), diode array detector (G1315D), and the results were 
analysed using Open Lab CDS software (Agilent Technologies; Mississauga, ON). The 
maximum wavelength (λ) was set at 275 nm, and an Agilent Poroshell 120 EC-C18, 4.6 × 
50 mm, 2.7μm column was used for compound and metabolite separation. A linear gradient 
mobile phase system with solvent A comprising of water with 0.1% formic acid and solvent 
B comprising of acetonitrile with 0.1% formic acid was used to elute the analytes at a flow 
rate of 1 mL/min. The 18-minute gradient elution program started with an initial condition 
of 15% mobile phase B and was held isocratically for 6 minutes. It was then gradually 
decreased to 90% mobile phase B where it was held for 3 minutes before returning to the 
initial conditions at 13 minutes. The column was equilibrated in the initial conditions for 5 
minutes before the start of another run. 
5.3.2 Sample preparation 
Stock standard solutions and quality control solutions (QCs) of C8-6-C8 (8 mg/mL) was 
prepared in chloroform while 50 mg/mL of C8-6-I and C8-6-N were separately prepared in 
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methanol and stored at -80oC. The standard working solutions were prepared by diluting 
the stock solution to yield the following concentrations: 0.04/0.4/1.6/2.4/3.2/4/5.6 mg/mL 
for C8-6-C8 and 0.2/0.4/4/8/16/24/32/ 40 mg/mL for C8-6-I. The calibration standards were 
prepared by spiking 1 µL of standard working solutions into a 5 µL aliquot of control liver 
microsomes, and then 10 µL of MgCl2 and 20 µL of SPP were added to the cocktail 
mixture. Subsequently, 164 µL of 100 mM potassium phosphate buffer was added to 
achieve a volume of 200 µL. Finally, 200 µL of cold acetonitrile was added to precipitate 
the proteins, and a final volume of 400 µL was considered to obtain the following final 
concentrations: 0.1/1/4/6/8/10/14 µg/mL for C8-6-C8, and 0.5/1/10/20/40/60/80/100 
µg/mL for C8-6-I. The medium cocktail was vortexed for 1 min followed by centrifugation 
in a VWR centrifuge at 14000×g for 10 min. Then 200 µL of the supernatant was placed 
in an HPLC vial, and 10 µL was injected into the HPLC. 
5.3.3 Bioanalytical method validation 
The bioanalytical method is being validated for specificity, linearity, accuracy, precision, 
recovery, and stability according to US Food and Drug Administration guideline (216). 
5.3.3.1 Specificity 
Specificity was assessed by analyzing pooled HLM, RLM, and MLM to determine the 
absence of endogenous substances with similar retention time as the analyte of interest.  
5.3.3.2 Linearity 
A standard curve was constructed by plotting known concentrations in the range of 0.1 
µg/mL to 14 µg/mL for C8-6-C8, and 0.5 µg/mL to 100 µg/mL for C8-6-I against the 
detector response peak area. The calibration standards also contain a blank sample (matrix 
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sample without analyte). Accuracy was set at ±15% for all standards except for the lower 
limit of quantification (LLOQ) which should be no more than ±20%. 
The standard that is three times the signal to noise ratio should be considered as the limit 
of detection (LOD). 
5.3.3.3 Accuracy and precision 
The accuracy and precision of the bioanalytical method will be determined in terms of 
intermediate precision (intraday and interday). The QCs consisted of LLOQ, low quality 
control (LQC), middle quality control (MQC), and high quality control (HQC), and had 
the following concentrations, for C8-6-C8: 0.1 µg/mL (LLOQ), 0.2 µg/mL (LQC), 7 µg/mL 
(MQC), and 11 µg/mL (HQC) while for C8-6-I: 0.5 µg/mL (LLOQ), 0.8 µg/mL (LQC), 50 
µg/mL (MQC), and 85 µg/mL (HQC). The QCs will be analysed in sextuplicate during the 
same day (intraday) and on three consecutive days (interday). The accuracy was expressed 
as the difference in percentage between the measured concentration and the nominal 
concentration for each sample. Precision will be determined using the coefficient of 
variation (CV).  
For accuracy, the mean value should be within ±15% of the nominal value, except LLOQ 
which should be no more than ±20%. The precision around the mean value should be within 
15% of the CV, except for LLOQ where it should not deviate by more than 20% of the CV. 
5.3.3.4 Recovery 
The absolute recovery of C8-6-C8, C8-6-I, and C8-6-N will be determined in the triplicate 
analysis of control microsomes spiked with the LLOQ, LQC, MQC, and HQC. The 
recovery will be calculated by comparing the peak areas of the extracted standards with the 
unextracted standards at the same concentration.  
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5.3.3.5 Stability 
The stability of samples at room temperature will be tested in triplicate by placing the 
LLOQ, LQC, MQC, and HQC at the bench top. Samples will be analysed at 12 and 24 
hours by comparison with freshly prepared samples at the same concentration.  
Additionally, the stability of samples in the autosampler will be established by placing the 
LLOQ, LQC, MQC, and HQC in the autosampler for 12 and 24 hours. Analytes of interest 
will be considered stable if the determined concentrations are within ±15% of the nominal 
value except for the LLOQ which can be no more than ±20%. 
5.4 Results and Discussion 
5.4.1 Bioanalytical method development 
 
Figure 5.1 HPLC chromatogram of C8-6-C8.  
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5.4.1.1 Specificity 
 
 
 
 
 
Figure 5.2 HPLC chromatograms of rat liver microsomes without C8-6-I (A) and rat 
liver microsomes spiked with 0.5 µg/mL C8-6-I (B). 
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5.4.1.2 Linearity 
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Figure 5.3 Calibration curve of C8-6-C8 in rat liver microsomes (A) and C8-6-I in 
mouse liver microsomes (B). 
 The C8-6-C8 was linear from 0.1 µg/mL to 14 µg/mL while C8-6-I was linear from 0.5 
µg/mL to 100 µg/mL 
An HPLC bioanalytical method has been developed and is currently being validated 
according to the US Food and Drug Administration guideline. Several challenges such as 
instrument problems and difficulty obtaining analytes prevented completion of the 
validation process. Future work will be focused on completing the bioanalytical method 
validation. 
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6.0 Chapter Six: General Discussion 
In this study, I established a novel tandem mass spectrometric fingerprint for three novel 
bifunctional compounds (C8-6-I, C8-6-N, and C8-6-C8) that our laboratory discovered as 
potential therapeutics for PD. Subsequently, I used the established tandem mass 
spectrometric fingerprint to develop a novel LC-MS and LC-MS/MS method for the 
unambiguous identification and structural elucidation of the phase I metabolites of C8-6-I, 
C8-6-N, and C8-6-C8 in HLM, MLM, and RLM. This is the first preclinical study to 
evaluate the tandem mass spectrometric behaviour, as well as to establish the metabolic 
profile of C8-6-I, C8-6-N, and C8-6-C8 in HLM, MLM, and RLM. The elucidation of the 
metabolic pathway of these bifunctional compounds can provide information that can 
direct future studies towards the improvement of the safety and efficacy of these 
compounds. Furthermore, the characterization of the metabolites will provide useful 
information about the least metabolically labile location for the inclusion of the 18F 
radioisotope on C8-6-I, C8-6-N, and C8-6-C8 as a guide for the development of PET 
imaging probes for diagnosis of PD. Comparison of the metabolic fate of C8-6-I, C8-6-N, 
and C8-6-C8 in HLM, MLM, and RLM will help us to determine the most appropriate 
animal model for future animal studies. In general, the outcome of this study will contribute 
to the development of predictive structural models to maximize biodistribution (high brain 
penetrance and AS selectivity) and minimize metabolic degradation (optimize lifetime). 
6.1 Tandem mass spectrometric analysis 
The tandem mass spectrometric analysis revealed the mass spectrometric behaviour of C8-
6-I, C8-6-N, and C8-6-C8. For example, we realized that the CE required for complete 
dissociation increased from C8-6-I, C8-6-N, to C8-6-C8 reflecting the energetic stability of 
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these bifunctional compounds. Interestingly, I hypothesized that caffeine dissociation 
would be the driving force in the tandem mass spectrometric fragmentation of C8-6-I, C8-
6-N, and C8-6-C8 but this was not the case as all three compounds had distinct 
fragmentation pathways and dissociation of caffeine moiety is only a minor pathway in the 
fragmentation of C8-6-N and C8-6-I. This suggests to us that when incorporated into these 
bifunctional compounds, the caffeine moiety may be more stable to fragmentation than 
either the nicotine or 1-aminoindan moieties. The fragmentation of the nicotine and 1-
aminoindan moieties occurs primarily in a saturated, unconjugated region, whereas 
caffeine possesses more extensive conjugation. This extensive conjugation and 
accompanying resonance effects for caffeine may be responsible for attenuating 
fragmentation. Hence, in the presence of nicotine or 1-aminoindan, caffeine dissociation 
in these bifunctional compounds is minor.  Furthermore, the fragmentation of C8-6-I, C8-
6-N, and C8-6-C8 produced a sequence of diagnostic product ions which I classified as first, 
second, and third cohort ion groups, as well as initial product ions. The first cohorts are 
product ions originating directly from the precursor ions, and subsequent dissociation (MS3 
analysis) of some of the first cohorts gives rise to second cohorts. MS3 analysis of the 
second cohorts gives rise to third cohorts and those product ions not found on the MS3 
spectrum of the first, second, and third cohorts are called initial product ions. The 
classification of these product ions provides useful information about their origin, and such 
information may serve as a guide when selecting diagnostic quantifier and qualifier ions 
for MRM methods. For example, a generalized MS/MS fingerprint was developed for a 
series of structurally similar novel drug delivery agents, namely gemini surfactants (187-
189), and the established CID-MS/MS fingerprint was used to develop a targeted MS 
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method for the quantification of the gemini surfactants within a cellular lysate (190-192). 
Additionally, the second and third cohort of product ions may be useful for developing an 
MRM3 method for the quantification of these bifunctional compounds in complex 
biological matrices. MRM3 plays a critical role in enhancing analytical selectivity during 
the quantification of compounds in complex biological matrices where there is an increased 
possibility of matrix interference with conventional MRM transitions. For instance, a loss 
of analytical selectivity was observed for quantifying plasma normetanephrine and 
metanephrine when using conventional LC-MRM due to matrix interferences (217-220). 
To address the issue, Wright et al., developed a multi-stage fragmentation (MRM3) for the 
measurement of plasma free metanephrine and normetanephrine (221). The developed 
MRM3 method improved the analytical selectivity of plasma free metanephrine and 
normetanephrine quantification with sufficient analytical sensitivity (221).  
Another interesting fact about the tandem mass spectrometric analysis is that through 
accurate mass measurement we discovered that a previously reported loss of acetaldehyde 
during caffeine fragmentation (194) is instead a loss of carbon dioxide. It was observed 
that the mass error of the product ion (A1) originating from the loss of acetaldehyde from 
C8-6-C8 is -85.2020 ppm, but when the NL is carbon dioxide, the mass error of A1 is 1.6384 
ppm (Table A.2, Appendix A). Interestingly, other product ions that originated from the 
loss of acetaldehyde had unacceptable mass errors, but when we proposed a new 
fragmentation mechanism involving the loss of carbon dioxide (Figure 3.4A), the mass 
error was found to be within the acceptable range (Table A.2, Appendix A).  
The diagnostic NLs observed in the fragmentation pathways can be used for targeted 
identification of the three bifunctional compounds and their metabolites in biological 
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matrices. For example, Bourcier et al., used diagnostic NLs identified from the 
fragmentation of 28 neurotransmitters and related compounds (181-185) to identify 
expected and unexpected metabolites in biological fluids (181). Additionally, Bourcier et 
al., used diagnostic NLs for the unambiguous differentiation of isomers, as well as the 
identification and localization of functional groups(186).  
Another instructive aspect of this work is that future MS/MS fragmentation of analogues 
containing caffeine moiety would be anticipated to occur elsewhere in the structure, and 
this is a powerful tool for identification in biological matrices. Conversely, bifunctional 
compounds without caffeine, for example, nicotine linked to 1-aminoindan (N-6-I), would 
also be expected to have a unique MS/MS fragmentation. For example, you could predict 
that fragmentation of N-6-I would occur exclusively at the 1-aminoindan moiety at a 
collision energy of 22 eV. This would be valuable for identifying the parent compound and 
also useful for identifying metabolites (for example, it can determine if a hydroxyl group 
is attached to nicotine or 1-aminoindan). 
6.2 Metabolism studies 
To determine the metabolic stability of C8-6-I, C8-6-N, and C8-6-C8 in HLM, MLM, and 
RLM, it was necessary to establish an LC-MS, as well as LC-MS/MS method for non-
targeted identification and structural elucidation of the associated metabolites. Previous 
tandem mass spectrometric analysis of C8-6-I, C8-6-N, and C8-6-C8 guided our design of 
an LC-MS and LC-MS/MS method. The developed LC-high-resolution MS method 
allowed us to detect and identify the metabolites of C8-6-I, C8-6-N, and C8-6-C8 by 
characterizing distinct peaks present in the reaction mixtures but absent in the negative 
control samples as shown in Figure 4.2, and Figure C.1, Appendix C. The identified 
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metabolites have a mass error of less than 7 ppm (Table B.1, Appendix B) confirming the 
projected molecular structures. Additionally, the tandem mass spectrometric analysis 
confirmed the expected molecular structures of the identified metabolites. This clearly 
shows that tandem mass spectrometry and accurate mass measurement are important in the 
structural elucidation of unknown metabolites.  
Two metabolites were each identified for C8-6-I (Figure 4.2A) and C8-6-N (Figure 4.2B) 
while no metabolites were detected for C8-6-C8 (Figure 4.2C) in HLM, MLM, and RLM. 
Upon characterization of the identified metabolites for C8-6-I and C8-6-N in HLM, MLM, 
and RLM, we realized that none of those metabolites originated from the caffeine moiety. 
This suggests that the caffeine moiety of these bifunctional compounds is metabolically 
stable in vitro. Interestingly, previous in vitro metabolism studies suggest that caffeine 
undergoes phase 1 metabolism to form the following metabolites: theobromine, 
theophylline, paraxanthine, and 1, 3, 7-trimethyluric acid (143, 208-210). Surprisingly, 
none of these metabolites was detected for C8-6-C8, as well as for the caffeine moiety of 
C8-6-I and C8-6-N. I speculated that the dimerization of caffeine would have conferred 
extra energetic stability to circumvent P450-mediated metabolism. Additionally, the low 
in vitro turnover rate of the enzymes involved in caffeine metabolism (143, 211) may be 
responsible for the metabolic stability of C8-6-C8, as well as the caffeine moiety of C8-6-I 
and C8-6-N. Interestingly, Istradefylline which is a caffeine analogue that is currently under 
development for treatment of the signs and symptoms of PD, was reported to undergo 
oxidative metabolism of the non-caffeine moiety, with the main metabolites (Figure 4.5) 
being M1 (4′‐O‐monodesmethylated) and M8 (1‐β‐hydroxylated) (data on file; Kyowa 
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Kirin Pharmaceutical Development, Inc.) suggesting that C8 functionalization of caffeine 
may confer metabolic stability.  
Furthermore, our study revealed that dealkylation (M1 and M3) and hydroxylation (M2 
and M4) are the common metabolic pathways for C8-6-I and C8-6-N in HLM, MLM, and 
RLM (Figure 4.4). Previous metabolism studies suggest that nicotine is metabolized to the 
following phase I metabolites: nicotine-Δ 1′ (5′) -iminium ion, 5'-hydroxynicotine, 
nornicotine, 2'-hydroxynicotine, 4-(methylamino)-1-(3- pyridyl)-1-butanone, 4-oxo-4-
(3-pyridyl) butanoic acid and 4- hydroxy-4-(3-pyridyl) butanoic acid(148); however, 
our study identified only a hydroxylated metabolite (M4) for the nicotine moiety of 
C8-6-N. Given that the 2'-hydroxylation of nicotine is a minor pathway for nicotine 
metabolism, we propose the 5'-position of nicotine as the location of the hydroxyl 
group on M4 (Figure 4.7B) because the 5'-hydroxylation pathway leads to the 
formation of cotinine which is the main metabolite of nicotine (148). The formation of 
cotinine involves two steps: (i) CYP2A6-mediated metabolism of nicotine to form 
nicotine-Δ 1′ (5′) -iminium ion which is in equilibrium with 5'-hydroxynicotine, and (ii) 
cytoplasmic aldehyde oxidase-mediated formation of cotinine (148). As microsomes 
do not contain cytoplasmic enzymes such as aldehyde oxidase, it is impossible to 
ascertain at this stage whether the hydroxyl group on M4 is further reduced to a ketone 
(cotinine).  
Furthermore, previous studies suggest that nicotine and some of its metabolites (such 
as cotinine) have neurotherapeutic effects for PD (222). This suggests that M4 may 
have similar neuroprotective effect as the parent compound (C8-6-N). More so, 2'-
hydroxylation of nicotine is an important step in the formation of 4-(methylamino)-1-
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(3- pyridyl)-1-butanone, 4-oxo-4-(3-pyridyl) butanoic acid and 4-hydroxy-4-(3-
pyridyl) butanoic acid (156); however, this is a minor pathway in nicotine metabolism. 
In fact, this pathway is toxicologically significant since 4-(methylamino)-1-(3- 
pyridyl)-1-butanone can be biotransformed to carcinogenic NNK (148). Fortunately, 
this pathway was not observed in the biotransformation of C8-6-N in HLM, RLM, and 
MLM.  
In addition, 1-aminoindan is a metabolite of rasagiline, and subsequent metabolism of 
1-aminoindan gives rise to 3-OH-AI (161-163). A hydroxylated metabolite of C8-6-I 
was identified, and tandem mass spectrometry suggests that the hydroxyl group is 
located on the 1-aminoindan moiety of C8-6-I. Given that 3-OH-AI is the only reported 
metabolite of 1-aminoindan, we propose that the hydroxyl group is located on the 3-
position of M2 (Figure 4.6 B). As a derivative of 1-aminoindan, 3-OH-AI might also 
have neuroprotective effects (168); therefore M2 might be neuroprotective too. 
Additionally, as M1 and M3 contain a caffeine moiety, they might also have potential 
neuroprotective properties.  
A major challenge encountered during the in vitro metabolism studies is the poor 
solubility of C8-6-C8. I discovered that C8-6-C8 had better solubility in chloroform than 
other organic solvents such as methanol, acetonitrile, and dimethyl sulfoxide. To 
ensure optimum P450 enzyme activity, the final organic solvent concentration in the 
samples was kept at 0.5%. Additionally, a recent study reported the negative impact of 
cytosolic contamination of liver microsomes on the interpretation of in vitro 
metabolism studies performed in microsomal fractions (223). Although there is a 
potential for cytosolic contamination of the liver microsomes used in this present 
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study, we did not observe any metabolite originating from aldehyde oxidase activity, 
such as the cotinine metabolite of C8-6-N, or conjugation reactions.    
6.3 Recommendation for development of PET Imaging probes for Parkinson’s 
disease 
Given the current challenges associated with the diagnosis of PD, PET imaging probes may 
be useful for early stage, as well as differential diagnosis of PD. Previous studies have used 
PET imaging probes to monitor the biochemical and neurological changes associated with 
PD. For example, Ouchi et al., used 11C-PK11195 and 11C-CFT (119) while Gerhard et al., 
used [11C] (R)-PK11195 and [18F]-DOPA(120) to monitor the alterations in 
neuroinflammatory reactions and the deletion of nerve terminals in the striatum as a 
measure of the integrity of dopaminergic neurons. Although the outcome of both studies 
provided useful information about the neuroanatomical changes associated with PD, it does 
not provide sufficient information that can help detect the onset of PD or aid in the 
differential diagnosis of PD in the presence of other neurodegenerative disorders.  
The overall advantage of these bifunctional compounds resides in their ability to interact 
with AS; therefore, radiolabeled analogues of these bifunctional compounds can be used 
to monitor AS misfolding as an indication of the onset of PD even in the presence of other 
neurodegenerative disorders. This is better than monitoring neuroanatomical changes such 
as deletion of dopaminergic nerve terminals because clinical manifestation of 
neuroanatomical abnormalities is dependent on the severity of the disease; for example, 
previous studies have shown that patients diagnosed with PD have lost about 60 to 80% of 
dopaminergic neurons prior to the onset of symptoms (22-25).  
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To develop these novel bifunctional compounds as PET imaging probes with clinical 
translational for diagnosing PD, they should have high binding affinity to AS, high 
specificity to AS, high sensitivity, high contrast ratio, high in vivo stability, low 
immunogenicity and toxicity (96). To achieve high in vivo stability, the 18F should be 
attached to the caffeine moiety of these bifunctional compounds because of its in vitro 
metabolic stability. Given the similarity in the metabolic pathways, mouse and rat may be 
useful surrogates for future animal studies of C8-6-I, C8-6-N, and C8-6-C8. Interestingly, 
our in vivo animal model for biodistribution studies is a mouse, and there is a good chance 
that the outcome of the biodistribution studies can be correlated to humans.       
6.4 Conclusion 
I established a novel tandem mass spectrometric fingerprint for C8-6-I, C8-6-N, and C8-6-
C8, and determined their metabolic profile in HLM, MLM, and RLM. The diagnostic 
product ions and neutral losses identified from the tandem mass spectrometric analysis can 
be used for qualitative and quantitative analysis of C8-6-I, C8-6-N, and C8-6-C8 in 
biological matrices. While C8-6-I and C8-6-N are metabolized in HLM, MLM, and RLM, 
C8-6-C8 is not metabolized. Given the similarity in the metabolic pathways, mouse and rat 
may be useful surrogates for future animal studies of C8-6-I, C8-6-N, and C8-6-C8. To 
ensure optimum in vivo biodistribution and lifetime, the 18F radioisotope should be attached 
to the caffeine moiety of C8-6-I, C8-6-N, and C8-6-C8. A rapid bioanalytical method has 
been developed for the quantification of C8-6-I, C8-6-N, and C8-6-C8 in HLM, MLM, and 
RLM. I have set up a validation protocol according to the US Food and Drug 
Administration guideline, and I achieved linearity of 0.1 µg/mL to 14 µg/mL for C8-6-C8 
and 0.5 µg/mL to 100 µg/mL for C8-6-I. Upon completion of validation, the method will 
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be used for the determination of the kinetic parameters of the in vitro metabolism of C8-6-
I, C8-6-N, and C8-6-C8 in HLM, MLM, and RLM. 
6.5 Future work 
Although previous studies have established the binding of C8-6-I, C8-6-N, and C8-6-C8 to 
AS (123), it is important to determine whether these bifunctional compounds also bind to 
the oligomeric, fibrillated, and phosphorylated forms of AS. Given the implication of the 
phosphorylated, oligomeric, and fibrillated forms of AS in the pathogenesis of PD, 
developing PET probes that can bind to these forms of AS will be important in determining 
the onset of PD. Interestingly, previous studies suggest that authentic phosphorylation of 
AS at serine-129 leads to an increase in fibril formation(13-17) and 90% of insoluble AS 
in Lewy bodies is phosphorylated (14, 224); therefore, if C8-6-I, C8-6-N, and C8-6-C8 bind 
to the phosphorylated, oligomeric, and fibrillated forms of AS, their radiolabeled forms 
may be used for detecting the onset of PD and also for monitoring disease progression. A 
good next step would be to determine the amino acids that define the binding region of C8-
6-I, C8-6-N, and C8-6-C8 on AS. Such information would be used to modify the structure 
of C8-6-I, C8-6-N, and C8-6-C8 if binding to the oligomeric, fibrillated, and phosphorylated 
forms of AS becomes challenging. 
Furthermore, previous studies suggest that the metabolites of 1-aminoindan (168) and 
nicotine (222) might also have neuroprotective effects. Thus, future studies should be 
directed toward evaluating the neurotherapeutic properties of M1, M2, M3, and M4. 
Although evaluating the neurotherapeutic potentials of the metabolites of C8-6-I, C8-6-N, 
and C8-6-C8 is beneficial, it is also imperative to determine their toxicity profile especially 
at this early stage of drug discovery and development.  
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Additionally, as the present study did not determine the effect of cytosolic enzymes in the 
biotransformation of C8-6-I, C8-6-N, and C8-6-C8 in HLM, MLM, and RLM, it is necessary 
to determine the phase II metabolic profile of C8-6-I, C8-6-N, and C8-6-C8, as well as the 
neurotherapeutic effects of the corresponding metabolites. Also, it is important to 
determine the P450 enzymes, as well as the conjugation enzymes involved in the in vitro 
metabolism of C8-6-I, C8-6-N, and C8-6-C8. Such reaction phenotyping studies can help 
predict and avoid pharmacokinetic variability and adverse drug reactions by indicating 
whether the P450 isoform is highly inducible (for example, CYP2B6) or polymorphically 
expressed (for instance, CYP2D6) (203). However, an appropriate analytical method is 
critical to the success of reaction phenotyping studies. 
Although the present study developed an HPLC method for the quantification of C8-6-I, 
C8-6-N, and C8-6-C8 in HLM, MLM, and RLM, it is important to mention that LC-MRM 
offers superior quantitative capabilities, high selectivity, and sensitivity through MRM 
mode. The developed HPLC method can be used for the determination of the enzyme 
kinetics of the in vitro metabolism of C8-6-I, C8-6-N, and C8-6-C8 in HLM, MLM, and 
RLM. Future studies for the quantification of C8-6-I, C8-6-N, and C8-6-C8 in complex 
biological matrices such as blood and plasma for determination of their pharmacokinetic 
parameters should utilize the established mass spectrometric fingerprint to develop an LC-
MRM-based analytical method. Such pharmacokinetic studies usually monitor very low 
concentrations of the test compounds which may not be achieved using an HPLC-
ultraviolet detection. A major challenge with quantification using LC-MRM is the need to 
develop isotopically labeled forms of the test compounds as internal standards; however, 
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the cost associated with developing isotopically labeled forms of C8-6-I, C8-6-N, and C8-
6-C8 can be circumvented by using differential isotopic labeling. 
Moreover, the effect of membrane transporters should be evaluated at this early stage of 
drug discovery to ascertain whether to modify the structure of these bifunctional 
compounds without affecting their efficacy. P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP) are two important efflux transporters that play a critical role in 
limiting the CNS activity of some neurotherapeutic agents by preventing their penetration 
across the BBB (225). In fact, P-gp and BCRP are also implicated in the neuropathology 
of PD (226, 227). Hence, it is important to ascertain the effect of these transporters in the 
disposition of C8-6-I, C8-6-N, and C8-6-C8 using a PD-pathological BBB model, as well as 
a non-PD-pathological BBB model. There are several case studies implicating either P-gp, 
BCRP or both in the low CNS activity of neurotherapeutic agents and a typical example is 
the novel anti-PD candidate drug FLZ (N-2-(4-hydroxy-phenyl)-ethyl]-2-(2,5-dimethoxy-
phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide) which showed low BBB 
penetration in rat brain (225). Given the role of P-gp and BCRP in both efflux of substrates 
across the BBB, as well as neuropathology of PD, a study was conducted to determine 
whether P-gp and BCRP play a role in the low BBB permeability of FLZ and also to 
examine the influence of PD-pathological BBB in the transport of FLZ (228). The study 
found greater expression of P-gp and BCRP in the PD-pathological BBB model associated 
with reduced in vitro BBB permeability of FLZ compared to the non-PD-pathological BBB 
model. The study concluded that P-gp but not BCRP is responsible for the low BBB 
permeability of FLZ (228). One way to address this challenge would be to co-administer 
P-gp inhibitors such as haloperidol or the use of novel drug delivery P-gp bypass systems 
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and pharmaceutical excipients such as chemosensitizers, natural and synthetic polymers, 
and formulation excipients used as P-gp inhibitors (229) 
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Figure A.1 The ESI-QqToF-MS spectrum of C8-6-C8 (A), C8-6-N (B), and C8-6-I(C). 
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Table A.1 Mass accuracies of C8-6-C8, C8-6-N, and C8-6-I obtained during single stage 
ESI-QqToF-MS analysis. 
Compound Molecular 
Formula 
Theoretical, 
m/z  
  
Observed, m/z Mass 
Accuracy 
(ppm) 
C8-6-C8 C22H31N8O4 471.2462 471.2468 1.2732 
C8-6-N  C23H33N6O2 425.2659 425.2660 0.2351 
C8-6-I C23H32N5O2 410.2550 410.2551 0.2438 
 
Table A.2 Mass accuracies of the MS/MS product ions of C8-6-C8 obtained during 
ESI-QqToF-MS/MS analysis. 
MS/MS 
Product ions, 
m/z 
Molecular 
Formula 
Theoretical, 
m/z  
  
Observed, m/z Mass 
Accuracy 
(ppm) 
 [A1] C21H31N8O2 427.2564 427.2571 1.6384 
 [A11] C20H30N7O2 400.2455 400.2466 2.7483 
 [A2] C20H28N7O3 414.2248 414.2230 -4.3455 
 [A21] C19H28N7O2 386.2298 386.2293 -1.2946 
 [A22] C19H28N7O 370.2349 370.2382 8.9132 
 [A22+] C18H28N7 342.2400 342.2401 0.2922 
 [A22++] C13H19N4 231.1604 231.1619 6.4890 
 [A23] C18H25N6O2 357.2033 357.2055 6.1589 
 [A24] C15H22N5O2 304.1768 304.1789 6.9038 
 [A4] C10H13N4O2 221.1033 221.1048 6.7841 
 
Table A.3 Mass accuracies of the MS/MS product ions of C8-6-N obtained during ESI-
QqToF-MS/MS analysis. 
MS/MS 
Product ions 
Designation 
Molecular 
Formula 
Theoretical, 
m/z  
  
Observed, m/z Mass 
Accuracy 
(ppm) 
 [B1] C18H28N5O2 346.2237 346.2243 1.7330 
 [B11] C14H21N4O2 277.1659 277.1666 2.5256 
 [B12] C14H19N4O2 275.1502 275.1516 5.0881 
 [B13] C9H11N4O2 207.0876 207.0891 7.2433 
 [B2] C17H26N5O2 332.2081 332.2074 -2.1071 
 [B21] C13H19N4O2 263.1502 263.1500 -0.7600 
 [1] C15H24N5O2 306.1924 306.1942 5.8786 
 [3] C12H18N3O 220.1444 220.1451 3.1797 
 [5] C7H10N3O2 168.0767 168.0781 8.3295 
 [8] C9H8N 130.0651 130.0659 6.1507 
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Table A.4 Mass accuracies of the MS/MS product ions of C8-6-I obtained during ESI-
QqToF-MS/MS analysis. 
MS/MS 
Product ions, 
m/z 
Molecular 
Formula 
Theoretical, 
m/z  
  
Observed, m/z Mass 
Accuracy 
(ppm) 
294.4 [C1] C14H24N5O2 294.1924 294.1912 -4.0790 
277.4 [C11] C14H21N4O2 277.1659 277.1660 0.3608 
 
Table A.5 Neutral losses observed from the fragmentation of all three bifunctional 
compounds. 
 
 C8-6-C8 C8-6-N C8-6-I 
 44 (CO2) 79 (C5H5N) 116 (C9H8) 
 27 (CN) 93 (C6H7N) 17 (NH3) 
 29 (CH2NH) 69 (C4H7N) 293 (C14H23N5O2) 
 57 (C2H3NO) 71 (C4H9N)  
 28 (CO) 139 (C9H17N)  
 110 (C5H6N2O2) 119 (C8H9N)  
 142 (C6H10N2O2) 176 (C11H16N2)  
Neutral losses (Da) 250 (C12H18N4O2) 148 (C9H12N2)  
 139 (C6H9N3O) 57 (C2H3NO)  
 193 (C10H15N3O) 230 (C15N22N2)  
 41 (C2H3N) 257 (C16H23N3)  
 276 (C14H20N4O2) 289 (C14H19N5O2)  
 303 (C15H21N5O2) 293 (C14H23N5O2)  
 206 (C9H10N4O2) 2 (H2)  
 208 (C9H12N4O2) 305 (C15H23N5O2)  
 194 (C8H10N4O2) 236 (C11H16N4O2)  
 32 (CH3OH) 319 (C16H25N5O2)  
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Figure A.2 Summary of MS/MS and MS3 analysis for C8-6-C8 (A), C8-6-N (B), and 
C8-6-I (C). 
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Figure A.3 MS3 spectra for C1 (A) and C11 (B). 
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Appendix B 
Table B.1 HPLC-high-resolution and tandem mass spectrometric data for C8-6-I and C8-6-N metabolites detected in human, 
mouse, and rat liver microsomes (HLM, MLM, and RLM). 
 
 
 
 
 
 
 
 
 
Metabolite 
Designation 
Metabolic 
Reaction 
Retention 
Time (min) 
Molecular 
Formular  
Exact 
Mass 
(m/z) 
Mass 
Error(ppm) 
Parent 
Compound 
Matrices 
M1 De-alkylation 11.23 C14H24N502 294.1924 0.000 C8-6-I HLM, MLM, RLM 
M2 Hydroxylation 11.64 C23H32N503 426.2499 6.8035 C8-6-I HLM, MLM, RLM 
M3 De-alkylation 11.25 C14H24N5O2 294.1924 0.0000 C8-6-N HLM, MLM, RLM 
M4 Hydroxylation 11.53 C23H33N6O3 441.2608 6.1188 C8-6-N HLM, MLM, RLM 
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Figure C.1 Total ion chromatogram of LC-MS analysis of samples from in vitro human liver 
microsomal metabolism of C8-6-I (A), C8-6-N (B), C8-6-C8 (C), and in vitro rat liver 
microsomal metabolism of C8-6-I (D), C8-6-N (E), C8-6-C8 (F). 
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